Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Clinical Reviews in Allergy & Immunology
Published in: Clinical Reviews in Allergy & Immunology 2-3/2010

01-04-2010

Evidence for the Use of Intravenous Immunoglobulins—A Review of the Literature

Authors: Shaye Kivity, Uriel Katz, Natalie Daniel, Udi Nussinovitch, Neophytos Papageorgiou, Yehuda Shoenfeld

Published in: Clinical Reviews in Allergy & Immunology | Issue 2-3/2010

Login to get access

Abstract

Intravenous immunoglobulins (IVIg) were first introduced in the middle of the twentieth century for the treatment of primary immunodeficiencies. In 1981, Paul Imbach noticed an improvement of immune-mediated thrombocytopenia, in patients receiving IVIg for immunodeficiencies. This opened a new era for the treatment of autoimmune conditions with IVIg. Since then, IVIg has become an important treatment option in a wide spectrum of diseases, including autoimmune and acute inflammatory conditions, most of them off-label (not included in the US Food and Drug Administration recommendation). A panel of immunologists and internists with experience in IVIg therapy reviewed the medical literature for published data concerning treatment with IVIg. The quality of evidence was assessed, and a summary of the available relevant literature in each disease was given. To our knowledge, this is the first all-inclusive comprehensive review, developed to assist the clinician when considering the use of IVIg in autoimmune diseases, immune deficiencies, and other conditions.
Literature
1.
Imbach P, Barandun S, Baumgartner C, Hirt A, Hofer F, Wagner HP (1981) High-dose intravenous gamma globulin therapy of refractory, in particular idiopathic thrombocytopenia in childhood. Helv Paediatr Acta 36:81–86PubMed
2.
Hunt SA, Baker DW, Chin MH, Cinquegrani MP, Feldman AM, Francis GS, Ganiats TG, Goldstein S, Gregoratos G, Jessup ML, Noble RJ, Packer M, Silver MA, Stevenson LW, Gibbons RJ, Antman EM, Alpert JS, Faxon DP, Fuster V, Gregoratos G, Jacobs AK, Hiratzka LF, Russell RO, Smith SC Jr (2001) ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the International Society for Heart and Lung Transplantation; endorsed by the Heart Failure Society of America. Circulation 104:2996–3007PubMedCrossRef
3.
Katz U, Shoenfeld Y (2005) Review: intravenous immunoglobulin therapy and thromboembolic complications. Lupus 14:802–808PubMedCrossRef
4.
Orbach H, Katz U, Sherer Y, Shoenfeld Y (2005) Intravenous immunoglobulin: adverse effects and safe administration. Clin Rev Allergy Immunol 29:173–184PubMedCrossRef
5.
Orbach H, Tishler M, Shoenfeld Y (2004) Intravenous immunoglobulin and the kidney—a two-edged sword. Semin Arthritis Rheum 34:593–601PubMedCrossRef
6.
Federici AB, Rand JH, Bucciarelli P, Budde U, van Genderen PJ, Mohri H, Meyer D, Rodeghiero F, Sadler JE (2000) Acquired von Willebrand syndrome: data from an international registry. Thromb Haemost 84:345–349PubMed
7.
Federici AB, Stabile F, Castaman G, Canciani MT, Mannucci PM (1998) Treatment of acquired von Willebrand syndrome in patients with monoclonal gammopathy of uncertain significance: comparison of three different therapeutic approaches. Blood 92:2707–2711PubMed
8.
Ben-Chetrit E, Putterman C (1992) Transient neutropenia induced by intravenous immune globulin. N Engl J Med 326:270–271PubMed
9.
El Alfy MS, Mokhtar GM, El-Laboudy MA, Khalifa AS (2006) Randomized trial of anti-D immunoglobulin versus low-dose intravenous immunoglobulin in the treatment of childhood chronic idiopathic thrombocytopenic purpura. Acta Haematol 115:46–52PubMedCrossRef
10.
Tarantino MD, Young G, Bertolone SJ, Kalinyak KA, Shafer FE, Kulkarni R, Weber LC, Davis ML, Lynn H, Nugent DJ (2006) Single dose of anti-D immune globulin at 75 microg/kg is as effective as intravenous immune globulin at rapidly raising the platelet count in newly diagnosed immune thrombocytopenic purpura in children. J Pediatr 148:489–494PubMedCrossRef
11.
Aukrust P, Gullestad L, Lappegard KT, Ueland T, Aass H, Wikeby L, Simonsen S, Froland SS, Mollnes TE (2001) Complement activation in patients with congestive heart failure: effect of high-dose intravenous immunoglobulin treatment. Circulation 104:1494–1500PubMedCrossRef
12.
McNamara DM, Holubkov R, Starling RC, Dec GW, Loh E, Torre-Amione G, Gass A, Janosko K, Tokarczyk T, Kessler P, Mann DL, Feldman AM (2001) Controlled trial of intravenous immune globulin in recent-onset dilated cardiomyopathy. Circulation 103:2254–2259PubMed
13.
Gullestad L, Aass H, Fjeld JG, Wikeby L, Andreassen AK, Ihlen H, Simonsen S, Kjekshus J, Nitter-Hauge S, Ueland T, Lien E, Froland SS, Aukrust P (2001) Immunomodulating therapy with intravenous immunoglobulin in patients with chronic heart failure. Circulation 103:220–225PubMed
14.
Kato S, Morimoto S, Hiramitsu S, Uemura A, Ohtsuki M, Kato Y, Miyagishima K, Mori N, Hishida H (2007) Successful high-dose intravenous immunoglobulin therapy for a patient with fulminant myocarditis. Heart Vessels 22:48–51PubMedCrossRef
15.
Stouffer GA, Sheahan RG, Lenihan DJ, Patel P, Lenihan DJ (2003) The current status of immune modulating therapy for myocarditis: a case of acute parvovirus myocarditis treated with intravenous immunoglobulin. Am J Med Sci 326:369–374PubMedCrossRef
16.
Ozdogu H, Boga C (2005) Fatal cardiac tamponade in a patient with Kawasaki disease. Heart Lung 34:257–259PubMedCrossRef
17.
Hunsaker DM, Hunsaker JC 3rd, Adams KC, Noonan JA, Ackermann DM (2003) Fatal Kawasaki disease due to coronary aneurysm rupture with massive cardiac tamponade. J Ky Med Assoc 101:233–238PubMed
18.
Soncagi A, Devrim I, Karagoz T, Dilber E, Celiker A, Ozen S, Secmeer G (2007) Septated pericarditis associated with Kawasaki disease: a brief case report. Turk J Pediatr 49:312–314PubMed
19.
Sherer Y, Kuechler S, Jose Scali J, Rovensky J, Levy Y, Zandman-Goddard G, Shoenfeld Y (2008) Low dose intravenous immunoglobulin in systemic lupus erythematosus: analysis of 62 cases. Isr Med Assoc J 10:55–57PubMed
20.
Peterlana D, Puccetti A, Simeoni S, Tinazzi E, Corrocher R, Lunardi C (2005) Efficacy of intravenous immunoglobulin in chronic idiopathic pericarditis: report of four cases. Clin Rheumatol 24:18–21PubMedCrossRef
21.
Shapiro S, Shoenfeld Y, Gilburd B, Sobel E, Lahat N (2002) Intravenous gamma globulin inhibits the production of matrix metalloproteinase-9 in macrophages. Cancer 95:2032–2037PubMedCrossRef
22.
Matsuura E, Kobayashi K, Inoue K, Shoenfeld Y (2005) Intravenous immunoglobulin and atherosclerosis. Clin Rev Allergy Immunol 29:311–319PubMedCrossRef
23.
Williams RV, Minich LL, Tani LY (2001) Pharmacological therapy for patients with Kawasaki disease. Paediatr Drugs 3:649–660PubMedCrossRef
24.
Newburger JW, Takahashi M, Gerber MA, Gewitz MH, Tani LY, Burns JC, Shulman ST, Bolger AF, Ferrieri P, Baltimore RS, Wilson WR, Baddour LM, Levison ME, Pallasch TJ, Falace DA, Taubert KA (2004) Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Pediatrics 114:1708–1733PubMedCrossRef
25.
Nussinovitch U, Shoenfeld Y (2007) Neonatal lupus erythematosus—cardiac manifestations and atrio-ventricular conduction block. Harefuah 146(940–944):998
26.
Kaaja R, Julkunen H (2003) Prevention of recurrence of congenital heart block with intravenous immunoglobulin and corticosteroid therapy: comment on the editorial by Buyon et al. Arthritis Rheum 48:280–281 author reply 281–282PubMedCrossRef
27.
Letko E, Miserocchi E, Daoud YJ, Christen W, Foster CS, Ahmed AR (2004) A nonrandomized comparison of the clinical outcome of ocular involvement in patients with mucous membrane (cicatricial) pemphigoid between conventional immunosuppressive and intravenous immunoglobulin therapies. Clin Immunol 111:303–310PubMedCrossRef
28.
Sami N, Letko E, Androudi S, Daoud Y, Foster CS, Ahmed AR (2004) Intravenous immunoglobulin therapy in patients with ocular-cicatricial pemphigoid: a long-term follow-up. Ophthalmology 111:1380–1382PubMedCrossRef
29.
LeHoang P, Cassoux N, George F, Kullmann N, Kazatchkine MD (2000) Intravenous immunoglobulin (IVIg) for the treatment of birdshot retinochoroidopathy. Ocul Immunol Inflamm 8:49–57PubMed
30.
Hamill RJ, Musher DM, Groover JE, Zavell PJ, Watson DA (1992) IgG antibody reactive with five serotypes of Streptococcus pneumoniae in commercial intravenous immunoglobulin preparations. J Infect Dis 166:38–42PubMed
31.
Pourpak Z, Aghamohammadi A, Sedighipour L, Farhoudi A, Movahedi M, Gharagozlou M, Chavoshzadeh Z, Jadid L, Rezaei N, Moin M (2006) Effect of regular intravenous immunoglobulin therapy on prevention of pneumonia in patients with common variable immunodeficiency. J Microbiol Immunol Infect 39:114–120PubMed
32.
Favre O, Leimgruber A, Nicole A, Spertini F (2005) Intravenous immunoglobulin replacement prevents severe and lower respiratory tract infections, but not upper respiratory tract and non-respiratory infections in common variable immune deficiency. Allergy 60:385–390PubMedCrossRef
33.
Lekstrom-Himes JA, Gallin JI (2000) Immunodeficiency diseases caused by defects in phagocytes. N Engl J Med 343:1703–1714PubMedCrossRef
34.
Katz U, Achiron A, Sherer Y, Shoenfeld Y (2007) Safety of intravenous immunoglobulin (IVIG) therapy. Autoimmun Rev 6:257–259PubMedCrossRef
35.
Misbah S (1996) Intravenous immunoglobulin in the Guillain–Barré syndrome. Products with low IgA content may be used in patients with total IgA deficiency. BMJ 313:1400PubMed
36.
Levy Y, Sherer Y, Ahmed A, Langevitz P, George J, Fabbrizzi F, Terryberry J, Meissner M, Lorber M, Peter JB, Shoenfeld Y (1999) A study of 20 SLE patients with intravenous immunoglobulin—clinical and serologic response. Lupus 8:705–712PubMedCrossRef
37.
Hundt M, Manger K, Dorner T, Grimbacher B, Kalden P, Rascu A, Weber D, Burmester GR, Peter HH, Kalden JR, Schmidt RE (2000) Treatment of acute exacerbation of systemic lupus erythematosus with high-dose intravenous immunoglobulin. Rheumatology (Oxford) 39:1301–1302CrossRef
38.
Schroeder JO, Zeuner RA, Euler HH, Loffler H (1996) High dose intravenous immunoglobulins in systemic lupus erythematosus: clinical and serological results of a pilot study. J Rheumatol 23:71–75PubMed
39.
Micheloud D, Calderon M, Caparrros M, D'Cruz DP (2007) Intravenous immunoglobulin therapy in severe lupus myocarditis: good outcome in three patients. Ann Rheum Dis 66:986–987PubMedCrossRef
40.
Sherer Y, Levy Y, Shoenfeld Y (1999) Marked improvement of severe cardiac dysfunction after one course of intravenous immunoglobulin in a patient with systemic lupus erythematosus. Clin Rheumatol 18:238–240PubMedCrossRef
41.
Arnal C, Piette JC, Leone J, Taillan B, Hachulla E, Roudot-Thoraval F, Papo T, Schaeffer A, Bierling P, Godeau B (2002) Treatment of severe immune thrombocytopenia associated with systemic lupus erythematosus: 59 cases. J Rheumatol 29:75–83PubMed
42.
Goodfield M, Davison K, Bowden K (2004) Intravenous immunoglobulin (IVIg) for therapy-resistant cutaneous lupus erythematosus (LE). J Dermatolog Treat 15:46–50PubMedCrossRef
43.
De Pita O, Bellucci AM, Ruffelli M, Girardelli CR, Puddu P (1997) Intravenous immunoglobulin therapy is not able to efficiently control cutaneous manifestations in patients with lupus erythematosus. Lupus 6:415–417PubMedCrossRef
44.
Lampropoulos CE, Hughes GR, DC DP (2007) Intravenous immunoglobulin in the treatment of resistant subacute cutaneous lupus erythematosus: a possible alternative. Clin Rheumatol 26:981–983PubMedCrossRef
45.
Genereau T, Chosidow O, Danel C, Cherin P, Herson S (1999) High-dose intravenous immunoglobulin in cutaneous lupus erythematosus. Arch Dermatol 135:1124–1125PubMedCrossRef
46.
Zandman-Goddard G, Levy Y, Shoenfeld Y (2005) Intravenous immunoglobulin therapy and systemic lupus erythematosus. Clin Rev Allergy Immunol 29:219–228PubMedCrossRef
47.
Noursadeghi M, Aqel N, Gibson P, Pasvol G (2006) Successful treatment of severe Kikuchi's disease with intravenous immunoglobulin. Rheumatology (Oxford) 45:235–237CrossRef
48.
Chen JS, Chang KC, Cheng CN, Tsai WH, Su IJ (2000) Childhood hemophagocytic syndrome associated with Kikuchi's disease. Haematologica 85:998–1000PubMed
49.
Vignes S, Wechsler B (1999) Still's disease in adults: treatment with intravenous immunoglobulins. Rev Med Interne 20(Suppl 4):419s–422sPubMedCrossRef
50.
Permal S, Wechsler B, Cabane J, Perrot S, Blum L, Imbert JC (1995) Treatment of Still disease in adults with intravenous immunoglobulins. Rev Med Interne 16:250–254PubMedCrossRef
51.
Liozon E, Ly K, Aubard Y, Vidal E (1999) Intravenous immunoglobulins for adult Still's disease and pregnancy. Rheumatology (Oxford) 38:1024–1025CrossRef
52.
Jayne DR, Chapel H, Adu D, Misbah S, O'Donoghue D, Scott D, Lockwood CM (2000) Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity. QJM 93:433–439PubMedCrossRef
53.
Jayne DR, Lockwood CM (1993) Pooled intravenous immunoglobulin in the management of systemic vasculitis. Adv Exp Med Biol 336:469–472PubMed
54.
Richter C, Schnabel A, Csernok E, De Groot K, Reinhold-Keller E, Gross WL (1995) Treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated systemic vasculitis with high-dose intravenous immunoglobulin. Clin Exp Immunol 101:2–7PubMed
55.
Levy Y, Sherer Y, George J, Langevitz P, Ahmed A, Bar-Dayan Y, Fabbrizzi F, Terryberry J, Peter J, Shoenfeld Y (1999) Serologic and clinical response to treatment of systemic vasculitis and associated autoimmune disease with intravenous immunoglobulin. Int Arch Allergy Immunol 119:231–238PubMedCrossRef
56.
Jayne DR, Lockwood CM (1996) Intravenous immunoglobulin as sole therapy for systemic vasculitis. Br J Rheumatol 35:1150–1153PubMedCrossRef
57.
Muso E, Ito-Ihara T, Ono T, Imai E, Yamagata K, Akamatsu A, Suzuki K (2004) Intravenous immunoglobulin (IVIg) therapy in MPO-ANCA related polyangiitis with rapidly progressive glomerulonephritis in Japan. Jpn J Infect Dis 57:S17–S18PubMed
58.
Danieli MG, Cappelli M, Malcangi G, Logullo F, Salvi A, Danieli G (2004) Long term effectiveness of intravenous immunoglobulin in Churg–Strauss syndrome. Ann Rheum Dis 63:1649–1654PubMedCrossRef
59.
Tsurikisawa N, Taniguchi M, Saito H, Himeno H, Ishibashi A, Suzuki S, Akiyama K (2004) Treatment of Churg–Strauss syndrome with high-dose intravenous immunoglobulin. Ann Allergy Asthma Immunol 92:80–87PubMedCrossRef
60.
Carmassi F, Morale M, Puccetti R, Pistelli F, Palla R, Bevilacqua G, Viacava P, Antonelli A, Mariani G (1992) Efficacy of intravenous immunoglobulin therapy in a case of autoimmune-mediated chronic active hepatitis. Clin Exp Rheumatol 10:13–17PubMed
61.
Malaguarnera M, Guccione N, Musumeci S, Brogna A, Motta M, Di Fazio I (2004) Intravenous immunoglobulin plus interferon-alpha in autoimmune hepatitis C. BioDrugs 18:63–70PubMedCrossRef
62.
Rostoker G, Desvaux-Belghiti D, Pilatte Y, Petit-Phar M, Philippon C, Deforges L, Terzidis H, Intrator L, Andre C, Adnot S, Bonin P, Bierling P, Remy P, Lagrue G, Lang P, Weil B (1994) High-dose immunoglobulin therapy for severe IgA nephropathy and Henoch–Schönlein purpura. Ann Intern Med 120:476–484PubMed
63.
Lamireau T, Rebouissoux L, Hehunstre JP (2001) Intravenous immunoglobulin therapy for severe digestive manifestations of Henoch–Schönlein purpura. Acta Paediatr 90:1081–1082PubMed
64.
Kusuda A, Migita K, Tsuboi M, Degawa M, Matsuoka N, Tominaga M, Kawakami A, Kawabe Y, Taguchi T, Eguchi K (1999) Successful treatment of adult-onset Henoch–Schönlein purpura nephritis with high-dose immunoglobulins. Intern Med 38:376–379PubMedCrossRef
65.
Villarreal IR, Ortega O, Vigil A, Gallar P, Oliet A, Garcia-Rubiales A, Jimenez E (1999) Henoch–Schönlein nephritis. Adverse effect of treatment with intravenous immunoglobulin. Nephrol Dial Transplant 14:795–797PubMedCrossRef
66.
Hamidou MA, Pottier MA, Dupas B (1996) Intravenous immunoglobulin in Henoch–Schönlein purpura. Ann Intern Med 125:1013–1014PubMed
67.
Matsuda M, Miki J, Oguchi K, Tabata K, Ikeda S (2003) Fasciitis in mixed connective tissue disease successfully treated with high-dose intravenous immunoglobulin. Intern Med 42:910–911PubMedCrossRef
68.
Ulmer A, Kotter I, Pfaff A, Fierlbeck G (2002) Efficacy of pulsed intravenous immunoglobulin therapy in mixed connective tissue disease. J Am Acad Dermatol 46:123–127PubMedCrossRef
69.
Levy Y, Amital H, Langevitz P, Nacci F, Righi A, Conforti L, Generini S, Matucci Cerinic M, Shoenfeld Y (2004) Intravenous immunoglobulin modulates cutaneous involvement and reduces skin fibrosis in systemic sclerosis: an open-label study. Arthritis Rheum 50:1005–1007PubMedCrossRef
70.
Ihn H, Mimura Y, Yazawa N, Jinnin M, Asano Y, Yamane K, Tamaki K (2007) High-dose intravenous immunoglobulin infusion as treatment for diffuse scleroderma. Br J Dermatol 156:1058–1060PubMedCrossRef
71.
Nacci F, Righi A, Conforti ML, Miniati I, Fiori G, Martinovic D, Melchiorre D, Sapir T, Blank M, Shoenfeld Y, Pignone AM, Cerinic MM (2007) Intravenous immunoglobulins improve the function and ameliorate joint involvement in systemic sclerosis: a pilot study. Ann Rheum Dis 66:977–979PubMedCrossRef
72.
Levy Y, Sherer Y, Langevitz P, Lorber M, Rotman P, Fabrizzi F, Shoenfeld Y (2000) Skin score decrease in systemic sclerosis patients treated with intravenous immunoglobulin—a preliminary report. Clin Rheumatol 19:207–211PubMedCrossRef
73.
Giannini EH, Lovell DJ, Silverman ED, Sundel RP, Tague BL, Ruperto N (1996) Intravenous immunoglobulin in the treatment of polyarticular juvenile rheumatoid arthritis: a phase I/II study. Pediatric Rheumatology Collaborative Study Group. J Rheumatol 23:919–924PubMed
74.
Oppermann J, Mobius D (1994) Therapeutical and immunological effects of methylprednisolone pulse therapy in comparison with intravenous immunoglobulin. Treatment in patients with juvenile chronic arthritis. Acta Univ Carol Med (Praha) 40:117–121
75.
Uziel Y, Laxer RM, Schneider R, Silverman ED (1996) Intravenous immunoglobulin therapy in systemic onset juvenile rheumatoid arthritis: a follow-up study. J Rheumatol 23:910–918PubMed
76.
Prieur AM, Adleff A, Debre M, Boulate P, Griscelli C (1990) High dose immunoglobulin therapy in severe juvenile chronic arthritis: long-term follow-up in 16 patients. Clin Exp Rheumatol 8:603–608PubMed
77.
Kanik KS, Yarboro CH, Naparstek Y, Plotz PH, Wilder RL (1996) Failure of low-dose intravenous immunoglobulin therapy to suppress disease activity in patients with treatment-refractory rheumatoid arthritis. Arthritis Rheum 39:1027–1029PubMedCrossRef
78.
Becker H, Mitropoulou G, Helmke K (1989) Immunomodulating therapy of rheumatoid arthritis by high-dose intravenous immunoglobulin. Klin Wochenschr 67:286–290PubMedCrossRef
79.
Maksymowych WP, Avina-Zubieta A, Luong M, Russell AS (1996) High dose intravenous immunoglobulin (IVIg) in severe refractory rheumatoid arthritis: no evidence for efficacy. Clin Exp Rheumatol 14:657–660PubMed
80.
Maeda H, Furonaka O, Matsushima K, Awaya Y, Kuwabara M (2001) Successful treatment of ‘malignant rheumatoid arthritis’ in Japan with pooled intravenous immunoglobulin. Rheumatology (Oxford) 40:955–956CrossRef
81.
Takahashi Y, Takata T, Hoshino M, Sakurai M, Kanazawa I (2003) Benefit of IVIG for long-standing ataxic sensory neuronopathy with Sjögren’s syndrome. IV immunoglobulin. Neurology 60:503–505PubMed
82.
Kizawa M, Mori K, Iijima M, Koike H, Hattori N, Sobue G (2006) Intravenous immunoglobulin treatment in painful sensory neuropathy without sensory ataxia associated with Sjögren’s syndrome. J Neurol Neurosurg Psychiatry 77:967–969PubMedCrossRef
83.
Molina JA, Benito-Leon J, Bermejo F, Jimenez-Jimenez FJ, Olivan J (1996) Intravenous immunoglobulin therapy in sensory neuropathy associated with Sjögren’s syndrome. J Neurol Neurosurg Psychiatry 60:699PubMedCrossRef
84.
Dalakas MC, Illa I, Dambrosia JM, Soueidan SA, Stein DP, Otero C, Dinsmore ST, McCrosky S (1993) A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med 329:1993–2000PubMedCrossRef
85.
Danieli MG, Calcabrini L, Marchetti A, Calabrese V, Pettinari L, Massaccesi C, Gabrielli A, Danieli G (2007) Intravenous immunoglobulin treatment in autoimmune diseases. Recenti Prog Med 98:322–326PubMed
86.
Saito E, Koike T, Hashimoto H, Miyasaka N, Ikeda Y, Hara M, Yamada H, Yoshida T, Harigai M, Ichikawa Y (2008) Efficacy of high-dose intravenous immunoglobulin therapy in Japanese patients with steroid-resistant polymyositis and dermatomyositis. Mod Rheumatol 18:34–44PubMedCrossRef
87.
Dalakas MC, Koffman B, Fujii M, Spector S, Sivakumar K, Cupler E (2001) A controlled study of intravenous immunoglobulin combined with prednisone in the treatment of IBM. Neurology 56:323–327PubMed
88.
Walter MC, Lochmuller H, Toepfer M, Schlotter B, Reilich P, Schroder M, Muller-Felber W, Pongratz D (2000) High-dose immunoglobulin therapy in sporadic inclusion body myositis: a double-blind, placebo-controlled study. J Neurol 247:22–28PubMedCrossRef
89.
Dalakas MC, Sonies B, Dambrosia J, Sekul E, Cupler E, Sivakumar K (1997) Treatment of inclusion-body myositis with IVIg: a double-blind, placebo-controlled study. Neurology 48:712–716PubMed
90.
Seider N, Beiran I, Scharf J, Miller B (2001) Intravenous immunoglobulin therapy for resistant ocular Behcet's disease. Br J Ophthalmol 85:1287–1288PubMedCrossRef
91.
Rewald E, Jaksic JC (1990) Behcet's syndrome treated with high-dose intravenous IgG and low-dose aspirin. J R Soc Med 83:652–653PubMed
92.
Schwartz RS, Gabriel DA, Aledort LM, Green D, Kessler CM (1995) A prospective study of treatment of acquired (autoimmune) factor VIII inhibitors with high-dose intravenous gamma globulin. Blood 86:797–804PubMed
93.
Crenier L, Ducobu J, des Grottes JM, Cerny J, Delaunoit C, Capel P (1996) Low response to high-dose intravenous immunoglobulin in the treatment of acquired factor VIII inhibitor. Br J Haematol 95:750–753PubMedCrossRef
94.
Yamamoto K, Takamatsu J, Saito H (2007) Intravenous immunoglobulin therapy for acquired coagulation inhibitors: a critical review. Int J Hematol 85:287–293PubMedCrossRef
95.
Dykes AC, Walker ID, Lowe GD, Tait RC (2001) Combined prednisolone and intravenous immunoglobulin treatment for acquired factor VIII inhibitors: a 2-year review. Haemophilia 7:160–163PubMedCrossRef
96.
Molica S, Musto P, Chiurazzi F, Specchia G, Brugiatelli M, Cicoira L, Levato D, Nobile F, Carotenuto M, Liso V, Rotoli B (1996) Prophylaxis against infections with low-dose intravenous immunoglobulins (IVIG) in chronic lymphocytic leukemia. Results of a crossover study. Haematologica 81:121–126PubMed
97.
Griffiths H, Brennan V, Lea J, Bunch C, Lee M, Chapel H (1989) Crossover study of immunoglobulin replacement therapy in patients with low-grade B-cell tumors. Blood 73:366–368PubMed
98.
Boughton BJ, Jackson N, Lim S, Smith N (1995) Randomized trial of intravenous immunoglobulin prophylaxis for patients with chronic lymphocytic leukaemia and secondary hypogammaglobulinaemia. Clin Lab Haematol 17:75–80PubMed
99.
Chapel HM, Lee M, Hargreaves R, Pamphilon DH, Prentice AG (1994) Randomised trial of intravenous immunoglobulin as prophylaxis against infection in plateau-phase multiple myeloma. The UK Group for Immunoglobulin Replacement Therapy in Multiple Myeloma. Lancet 343:1059–1063PubMedCrossRef
100.
Gimesi A, Eibl M, Koos R, Somlo P, Magyarossy E, Kardos G, Fazekas E, Schmidt M, Borsi J, Schuler D (1992) Immunoglobulin prophylaxis during intensive treatment of acute lymphoblastic leukemia in children. Acta Paediatr Hung 32:115–125PubMed
101.
Sumer T, Abumelha A, al-Mulhim I, al-Fadil M (1989) Treatment of fever and neutropenia with antibiotics versus antibiotics plus intravenous gamma globulin in childhood leukemia. Eur J Pediatr 148:401–402PubMedCrossRef
102.
Bunch C (1988) Immunoglobulin replacement in chronic lymphocytic leukaemia. Nouv Rev Fr Hematol 30:419–422PubMed
103.
Musto P, Brugiatelli M, Carotenuto M (1995) Prophylaxis against infections with intravenous immunoglobulins in multiple myeloma. Br J Haematol 89:945–946PubMed
104.
Chapel H, Griffiths H, Brennan V, Bunch C, Lea J, Lee M (1991) Hypogammaglobulinaemia in low grade B cell tumours; significance and therapy. Immunol Invest 20:187–191PubMedCrossRef
105.
Ballester OF, Saba HI, Moscinski LC, Nelson R, Foulis P (1992) Pure red cell aplasia: treatment with intravenous immunoglobulin concentrate. Semin Hematol 29:106–108PubMed
106.
Clauvel JP, Vainchenker W, Herrera A, Dellagi K, Vinci G, Tabilio A, Lacombe C (1983) Treatment of pure red cell aplasia by high dose intravenous immunoglobulins. Br J Haematol 55:380–382PubMedCrossRef
107.
Tang JW, Lau JS, Wong SY, Cheung JL, Chan CH, Wong KF, Wong A, Chan PK (2007) Dose-by-dose virological and hematological responses to intravenous immunoglobulin in an immunocompromised patient with persistent parvovirus B19 infection. J Med Virol 79:1401–1405PubMedCrossRef
108.
Liang TB, Li DL, Yu J, Bai XL, Liang L, Xu SG, Wang WL, Shen Y, Zhang M, Zheng SS (2007) Pure red cell aplasia due to parvovirus B19 infection after liver transplantation: a case report and review of the literature. World J Gastroenterol 13:2007–2010PubMed
109.
Subtirelu MM, Flynn JT, Schechner RS, Pullman JM, Feuerstein D, Del Rio M (2005) Acute renal failure in a pediatric kidney allograft recipient treated with intravenous immunoglobulin for parvovirus B19 induced pure red cell aplasia. Pediatr Transplant 9:801–804PubMedCrossRef
110.
Song KW, Mollee P, Patterson B, Brien W, Crump M (2002) Pure red cell aplasia due to parvovirus following treatment with CHOP and rituximab for B-cell lymphoma. Br J Haematol 119:125–127PubMedCrossRef
111.
Castelli R, Vismara A, Pavia G, Dagani R, Porro T (2002) Relapsing pure red cell aplasia associated with B-cell chronic lymphocytic leukemia successfully treated by intravenous immunoglobulin concentrate. Ann Ital Med Int 17:47–50PubMed
112.
Choi SH, Chang SP, Won JC, Lee JS, Chi HS, Yang WS, Park SK (2002) A case of persistent anemia in a renal transplant recipient: association with parvovirus B19 infection. Scand J Infect Dis 34:71–75PubMedCrossRef
113.
Borkowski J, Amrikachi M, Hudnall SD (2000) Fulminant parvovirus infection following erythropoietin treatment in a patient with acquired immunodeficiency syndrome. Arch Pathol Lab Med 124:441–445PubMed
114.
Koduri PR, Kumapley R, Valladares J, Teter C (1999) Chronic pure red cell aplasia caused by parvovirus B19 in AIDS: use of intravenous immunoglobulin—a report of eight patients. Am J Hematol 61:16–20PubMedCrossRef
115.
Chuhjo T, Nakao S, Matsuda T (1999) Successful treatment of persistent erythroid aplasia caused by parvovirus B19 infection in a patient with common variable immunodeficiency with low-dose immunoglobulin. Am J Hematol 60:222–224PubMedCrossRef
116.
Koduri PR, Kumapley R, Khokha ND, Patel AR (1997) Red cell aplasia caused by parvovirus B19 in AIDS: use of i.v. immunoglobulin. Ann Hematol 75:67–68PubMedCrossRef
117.
Fuller A, Moaven L, Spelman D, Spicer WJ, Wraight H, Curtis D, Leydon J, Doultree J, Locarnini S (1996) Parvovirus B19 in HIV infection: a treatable cause of anemia. Pathology 28:277–280PubMedCrossRef
118.
Ramratnam B, Gollerkeri A, Schiffman FJ, Rintels P, Flanigan TP (1995) Management of persistent B19 parvovirus infection in AIDS. Br J Haematol 91:90–92PubMedCrossRef
119.
Mant MJ (1994) Chronic idiopathic pure red cell aplasia: successful treatment during pregnancy and durable response to intravenous immunoglobulin. J Intern Med 236:593–595PubMedCrossRef
120.
Ilan Y, Naparstek Y (1993) Pure red cell aplasia associated with systemic lupus erythematosus: remission after a single course of intravenous immunoglobulin. Acta Haematol 89:152–154PubMedCrossRef
121.
Ramage JK, Hale A, Gane E, Cohen B, Boyle M, Mufti G, Williams R (1994) Parvovirus B19-induced red cell aplasia treated with plasmapheresis and immunoglobulin. Lancet 343:667–668PubMedCrossRef
122.
McGuire WA, Yang HH, Bruno E, Brandt J, Briddell R, Coates TD, Hoffman R (1987) Treatment of antibody-mediated pure red-cell aplasia with high-dose intravenous gamma globulin. N Engl J Med 317:1004–1008PubMed
123.
Karmochkine M, Oksenhendler E, Leruez-Ville M, Jaccard A, Morinet F, Herson S (1995) Persistent parvovirus B19 infection and pure red cell aplasia in Waldenstrom's macroglobulinemia: successful treatment with high-dose intravenous immunoglobulin. Am J Hematol 50:227–228PubMedCrossRef
124.
Mohri H, Motomura S, Kanamori H, Matsuzaki M, Watanabe S, Maruta A, Kodama F, Okubo T (1998) Clinical significance of inhibitors in acquired von Willebrand syndrome. Blood 91:3623–3629PubMed
125.
Viallard JF, Pellegrin JL, Vergnes C, Borel-Derlon A, Clofent-Sanchez G, Nurden AT, Leng B, Nurden P (1999) Three cases of acquired von Willebrand disease associated with systemic lupus erythematosus. Br J Haematol 105:532–537PubMedCrossRef
126.
Sadowitz PD, Dubowy RL (1990) Intravenous immunoglobulin in the treatment of aplastic anemia. Am J Pediatr Hematol Oncol 12:198–200PubMedCrossRef
127.
Bergen GA, Sakalosky PE, Sinnott JT (1996) Transient aplastic anemia caused by parvovirus B19 infection in a heart transplant recipient. J Heart Lung Transplant 15:843–845PubMed
128.
Sherer Y, Levy Y, Fabbrizzi F, Shoenfeld Y (2000) Treatment of hematologic disorders other than immune thrombocytopenic purpura with intravenous immunoglobulin (IVIg)—report of seven cases and review of the literature. Eur J Intern Med 11:85–88PubMedCrossRef
129.
Flores G, Cunningham-Rundles C, Newland AC, Bussel JB (1993) Efficacy of intravenous immunoglobulin in the treatment of autoimmune hemolytic anemia: results in 73 patients. Am J Hematol 44:237–242PubMedCrossRef
130.
Bux J, Behrens G, Jaeger G, Welte K (1998) Diagnosis and clinical course of autoimmune neutropenia in infancy: analysis of 240 cases. Blood 91:181–186PubMed
131.
Hilgartner MW, Bussel J (1987) Use of intravenous gamma globulin for the treatment of autoimmune neutropenia of childhood and autoimmune hemolytic anemia. Am J Med 83:25–29PubMedCrossRef
132.
Mathew P, Chen G, Wang W (1997) Evans syndrome: results of a national survey. J Pediatr Hematol Oncol 19:433–437PubMedCrossRef
133.
Scaradavou A, Bussel J (1995) Evans syndrome. Results of a pilot study utilizing a multiagent treatment protocol. J Pediatr Hematol Oncol 17:290–295PubMedCrossRef
134.
Nuss R, Wang W (1987) Intravenous gamma globulin for thrombocytopenia in children with Evans syndrome. Am J Pediatr Hematol Oncol 9:164–167PubMedCrossRef
135.
Chang DK, Yoo DH, Kim TH, Jun JB, Lee IH, Bae SC, Kim IS, Kim SY (2001) Induction of remission with intravenous immunoglobulin and cyclophosphamide in steroid-resistant Evans' syndrome associated with dermatomyositis. Clin Rheumatol 20:63–66PubMedCrossRef
136.
Kaplan C, Murphy MF, Kroll H, Waters AH (1998) Feto-maternal alloimmune thrombocytopenia: antenatal therapy with IvIgG and steroids—more questions than answers. European Working Group on FMAIT. Br J Haematol 100:62–65PubMedCrossRef
137.
Cordonnier C, Chevret S, Legrand M, Rafi H, Dhedin N, Lehmann B, Bassompierre F, Gluckman E (2003) Should immunoglobulin therapy be used in allogeneic stem-cell transplantation? A randomized, double-blind, dose effect, placebo-controlled, multicenter trial. Ann Intern Med 139:8–18PubMed
138.
Zikos P, Van Lint MT, Lamparelli T, Gualandi F, Occhini D, Mordini N, Berisso G, Bregante S, Bacigalupo A (1998) A randomized trial of high dose polyvalent intravenous immunoglobulin (HDIgG) vs. cytomegalovirus (CMV) hyperimmune IgG in allogeneic hemopoietic stem cell transplants (HSCT). Haematologica 83:132–137PubMed
139.
Sullivan KM, Storek J, Kopecky KJ, Jocom J, Longton G, Flowers M, Siadak M, Nims J, Witherspoon RP, Anasetti C, Appelbaum FR, Bowden RA, Buckner CD, Crawford SW, Deeg HJ, Hansen JA, McDonald GB, Sanders JE, Storb R (1996) A controlled trial of long-term administration of intravenous immunoglobulin to prevent late infection and chronic graft-vs.-host disease after marrow transplantation: clinical outcome and effect on subsequent immune recovery. Biol Blood Marrow Transplant 2:44–53PubMed
140.
Winston DJ, Ho WG, Bartoni K, Champlin RE (1993) Intravenous immunoglobulin and CMV-seronegative blood products for prevention of CMV infection and disease in bone marrow transplant recipients. Bone Marrow Transplant 12:283–288PubMed
141.
Winston DJ, Antin JH, Wolff SN, Bierer BE, Small T, Miller KB, Linker C, Kaizer H, Lazarus HM, Petersen FB, Cowan MJ, Ho WG, Wingard JR, Schiller GJ, Territo MC, Jiao J, Petrarca MA, Tonetta SA (2001) A multicenter, randomized, double-blind comparison of different doses of intravenous immunoglobulin for prevention of graft-versus-host disease and infection after allogeneic bone marrow transplantation. Bone Marrow Transplant 28:187–196PubMedCrossRef
142.
Wolff SN, Fay JW, Herzig RH, Greer JP, Dummer S, Brown RA, Collins RH, Stevens DA, Herzig GP (1993) High-dose weekly intravenous immunoglobulin to prevent infections in patients undergoing autologous bone marrow transplantation or severe myelosuppressive therapy. A study of the American Bone Marrow Transplant Group. Ann Intern Med 118:937–942PubMed
143.
Sullivan KM, Kopecky KJ, Jocom J, Fisher L, Buckner CD, Meyers JD, Counts GW, Bowden RA, Peterson FB, Witherspoon RP et al (1990) Immunomodulatory and antimicrobial efficacy of intravenous immunoglobulin in bone marrow transplantation. N Engl J Med 323:705–712PubMed
144.
Alcock GS, Liley H (2002) Immunoglobulin infusion for isoimmune haemolytic jaundice in neonates. Cochrane Database Syst Rev 3:CD003313PubMed
145.
Gottstein R, Cooke RW (2003) Systematic review of intravenous immunoglobulin in haemolytic disease of the newborn. Arch Dis Child Fetal Neonatal Ed 88:F6–F10PubMedCrossRef
146.
Kohan AI, Niborski RC, Rey JA, Amerise G, Vazquez MI, Zani N, Calahonra R, Binaghi A, Sanchez Avalos J (1994) High-dose intravenous immunoglobulin in non-ABO transfusion incompatibility. Vox Sang 67:195–198PubMedCrossRef
147.
Woodcock BE, Walker S, Adams K (1993) Haemolytic transfusion reaction—successful attenuation with methylprednisolone and high dose immunoglobulin. Clin Lab Haematol 15:59–61PubMedCrossRef
148.
Win N, Doughty H, Telfer P, Wild BJ, Pearson TC (2001) Hyperhemolytic transfusion reaction in sickle cell disease. Transfusion 41:323–328PubMedCrossRef
149.
Win N, Yeghen T, Needs M, Chen FE, Okpala I (2004) Use of intravenous immunoglobulin and intravenous methylprednisolone in hyperhaemolysis syndrome in sickle cell disease. Hematology 9:433–436PubMedCrossRef
150.
Cullis JO, Win N, Dudley JM, Kaye T (1995) Post-transfusion hyperhaemolysis in a patient with sickle cell disease: use of steroids and intravenous immunoglobulin to prevent further red cell destruction. Vox Sang 69:355–357PubMedCrossRef
151.
Robson WL, Fick GH, Jadavji T, Leung AK (1991) The use of intravenous gamma globulin in the treatment of typical hemolytic uremic syndrome. Pediatr Nephrol 5:289–292PubMedCrossRef
152.
Sheth KJ, Gill JC, Leichter HE (1990) High-dose intravenous gamma globulin infusions in hemolytic–uremic syndrome: a preliminary report. Am J Dis Child 144:268–270PubMed
153.
Centurioni R, Bobbio-Pallavicini E, Porta C, Rodeghiero F, Gugliotta L, Billio A, Tacconi F, Ascari E (1995) Treatment of thrombotic thrombocytopenic purpura with high-dose immunoglobulins. Results in 17 patients. Italian Cooperative Group for TTP. Haematologica 80:325–331PubMed
154.
Dervenoulas J, Tsirigotis P, Bollas G, Koumarianou AA, Pappa V, Mantzios G, Xiros N, Economopoulos T, Papageorgiou E, Pappa M, Raptis SA (2001) Efficacy of intravenous immunoglobulin in the treatment of thrombotic thrombocytopaenic purpura. A study of 44 cases. Acta Haematol 105:204–208PubMedCrossRef
155.
Winder A, Shoenfeld Y, Hochman R, Keren G, Levy Y, Eldor A (1998) High-dose intravenous gamma-globulins for heparin-induced thrombocytopenia: a prompt response. J Clin Immunol 18:330–334PubMedCrossRef
156.
Prull A, Nechwatal R, Riedel H, Maurer W (1992) The therapy of the heparin-induced thrombosis–thrombocytopenia syndrome with immunoglobulins. Dtsch Med Wochenschr 117:1838–1842PubMedCrossRef
157.
Jahnke L, Applebaum S, Sherman LA, Greenberger PA, Green D (1994) An evaluation of intravenous immunoglobulin in the treatment of human immunodeficiency virus-associated thrombocytopenia. Transfusion 34:759–764PubMedCrossRef
158.
Godeau B, Chevret S, Varet B, Lefrere F, Zini JM, Bassompierre F, Cheze S, Legouffe E, Hulin C, Grange MJ, Fain O, Bierling P (2002) Intravenous immunoglobulin or high-dose methylprednisolone, with or without oral prednisone, for adults with untreated severe autoimmune thrombocytopenic purpura: a randomised, multicentre trial. Lancet 359:23–29PubMedCrossRef
159.
Jacobs P, Wood L (1989) The comparison of gamma globulin to steroids in treating adult immune thrombocytopenia. An interim analysis. Blut 59:92–95PubMedCrossRef
160.
Blanchette VS, Luke B, Andrew M, Sommerville-Nielsen S, Barnard D, de Veber B, Gent M (1993) A prospective, randomized trial of high-dose intravenous immune globulin G therapy, oral prednisone therapy, and no therapy in childhood acute immune thrombocytopenic purpura. J Pediatr 123:989–995PubMedCrossRef
161.
Duru F, Fisgin T, Yarali N, Kara A (2002) Clinical course of children with immune thrombocytopenic purpura treated with intravenous immunoglobulin G or megadose methylprednisolone or observed without therapy. Pediatr Hematol Oncol 19:219–225PubMedCrossRef
162.
Rarick MU, Montgomery T, Groshen S, Sullivan-Halley J, Jamin D, Mazumder A, Gill PS, Loureiro C, Levine AM (1991) Intravenous immunoglobulin in the treatment of human immunodeficiency virus-related thrombocytopenia. Am J Hematol 38:261–266PubMedCrossRef
163.
Majluf-Cruz A, Luna-Castanos G, Huitron S, Nieto-Cisneros L (1998) Usefulness of a low-dose intravenous immunoglobulin regimen for the treatment of thrombocytopenia associated with AIDS. Am J Hematol 59:127–132PubMedCrossRef
164.
Colovic M, Dimitrijevic M, Sonnenburg C, Suvajdzic N, Donfrid M, Bogdanovic A (2003) Clinical efficacy and safety of a novel intravenous immunoglobulin preparation in adult chronic ITP. Hematol J 4:358–362PubMedCrossRef
165.
Godeau B, Lesage S, Divine M, Wirquin V, Farcet JP, Bierling P (1993) Treatment of adult chronic autoimmune thrombocytopenic purpura with repeated high-dose intravenous immunoglobulin. Blood 82:1415–1421PubMed
166.
Mueller-Eckhardt C, Kuenzlen E, Thilo-Korner D, Pralle H (1983) High-dose intravenous immunoglobulin for post-transfusion purpura. N Engl J Med 308:287PubMed
167.
Becker T, Panzer S, Maas D, Kiefel V, Sprenger R, Kirschbaum M, Mueller-Eckhardt C (1985) High-dose intravenous immunoglobulin for post-transfusion purpura. Br J Haematol 61:149–155PubMedCrossRef
168.
Walker WS, Yap PL, Kilpatrick DC, Boulton FE, Crawford RJ, Sang CT (1988) Post-transfusion purpura following open heart surgery: management by high dose intravenous immunoglobulin infusion. Ann Hematol 57:323–325
169.
Asci G, Toz H, Ozkahya M, Cagirgan S, Duman S, Sezis S, Ok E (2006) High-dose immunoglobulin therapy in renal transplant recipients with hemophagocytic histiocytic syndrome. J Nephrol 19:322–326PubMed
170.
Chen CJ, Huang YC, Jaing TH, Hung IJ, Yang CP, Chang LY, Lin TY (2004) Hemophagocytic syndrome: a review of 18 pediatric cases. J Microbiol Immunol Infect 37:157–163PubMed
171.
Chen RL, Lin KH, Lin DT, Su IJ, Huang LM, Lee PI, Hseih KH, Lin KS, Lee CY (1995) Immunomodulation treatment for childhood virus-associated haemophagocytic lymphohistiocytosis. Br J Haematol 89:282–290PubMedCrossRef
172.
Ningsanond V (2000) Infection associated hemophagocytic syndrome: a report of 50 children. J Med Assoc Thai 83:1141–1149PubMed
173.
Freeman B, Rathore MH, Salman E, Joyce MJ, Pitel P (1993) Intravenously administered immune globulin for the treatment of infection-associated hemophagocytic syndrome. J Pediatr 123:479–481PubMedCrossRef
174.
Hot A, Madoux MH, Viard JP, Coppere B, Ninet J (2008) Successful treatment of cytomegalovirus-associated hemophagocytic syndrome by intravenous immunoglobulins. Am J Hematol 83:159–162PubMedCrossRef
175.
Benito-Leon J, Lopez-Rios F, Rodriguez-Martin FJ, Madero S, Ruiz J (1998) Rapidly deteriorating polyneuropathy associated with osteosclerotic myeloma responsive to intravenous immunoglobulin and radiotherapy. J Neurol Sci 158:113–117PubMedCrossRef
176.
Huang CC, Chu CC (1996) Poor response to intravenous immunoglobulin therapy in patients with Castleman's disease and the POEMS syndrome. J Neurol 243:726–727PubMedCrossRef
177.
Chang YJ, Huang CC, Chu CC (1996) Intravenous immunoglobulin therapy in POEMS syndrome: a case report. Zhonghua Yi Xue Za Zhi (Taipei) 58:366–369
178.
Cantarovich M, Barkun JS, Forbes RD, Kosiuk JP, Tchervenkov JI (1998) Successful treatment of post-transplant lymphoproliferative disorder with interferon-alpha and intravenous immunoglobulin. Clin Transplant 12:109–115PubMed
179.
Leroy F, Sechet A, Abou Ayache R, Thierry A, Belmouaz S, Desport E, Bauwens M, Bridoux F, Touchard G (2006) Cytomegalovirus prophylaxis with intravenous polyvalent immunoglobulin in high-risk renal transplant recipients. Transplant Proc 38:2324–2326PubMedCrossRef
180.
The National Institute of Child Health and Human Developments Intravenous Immunoglobulin Study Group (1991) Intravenous immune globulin for the prevention of bacterial infections in children with symptomatic human immunodeficiency virus infection. N Engl J Med 325:73–80CrossRef
181.
Olopoenia L, Young M, White D, Barnes S, Rahbar F, Fomufod A (1997) Intravenous immunoglobulin in symptomatic and asymptomatic children with perinatal HIV infection. J Natl Med Assoc 89:543–547PubMed
182.
Goldring JD, Molyneux ME, Taylor T, Wirima J, Hommel M (1992) Plasmodium falciparum: diversity of isolates from Malawi in their cytoadherence to melanoma cells and monocytes in vitro. Br J Haematol 81:413–418PubMedCrossRef
183.
Sabchareon A, Burnouf T, Ouattara D, Attanath P, Bouharoun-Tayoun H, Chantavanich P, Foucault C, Chongsuphajaisiddhi T, Druilhe P (1991) Parasitologic and clinical human response to immunoglobulin administration in falciparum malaria. Am J Trop Med Hyg 45:297–308PubMed
184.
Gonzalez H, Sunnerhagen KS, Sjoberg I, Kaponides G, Olsson T, Borg K (2006) Intravenous immunoglobulin for post-polio syndrome: a randomised controlled trial. Lancet Neurol 5:493–500PubMedCrossRef
185.
Farbu E, Rekand T, Vik-Mo E, Lygren H, Gilhus NE, Aarli JA (2007) Post-polio syndrome patients treated with intravenous immunoglobulin: a double-blinded randomized controlled pilot study. Eur J Neurol 14:60–65PubMedCrossRef
186.
Kaponides G, Gonzalez H, Olsson T, Borg K (2006) Effect of intravenous immunoglobulin in patients with post-polio syndrome—an uncontrolled pilot study. J Rehabil Med 38:138–140PubMedCrossRef
187.
Laupland KB, Kirkpatrick AW, Delaney A (2007) Polyclonal intravenous immunoglobulin for the treatment of severe sepsis and septic shock in critically ill adults: a systematic review and meta-analysis. Crit Care Med 35:2686–2692PubMedCrossRef
188.
Hamdan A, Green P, Mendelson E, Kramer MR, Pitlik S, Weinberger M (2002) Possible benefit of intravenous immunoglobulin therapy in a lung transplant recipient with West Nile virus encephalitis. Transpl Infect Dis 4:160–162PubMedCrossRef
189.
Shimoni Z, Niven MJ, Pitlick S, Bulvik S (2001) Treatment of West Nile virus encephalitis with intravenous immunoglobulin. Emerg Infect Dis 7:759PubMedCrossRef
190.
The Intravenous Immunoglobulin Collaborative Study Group (1992) Prophylactic intravenous administration of standard immune globulin as compared with core-lipopolysaccharide immune globulin in patients at high risk of postsurgical infection. N Engl J Med 327:234–240
191.
Glinz W, Grob PJ, Nydegger UE, Ricklin T, Stamm F, Stoffel D, Lasance A (1985) Polyvalent immunoglobulins for prophylaxis of bacterial infections in patients following multiple trauma. A randomized, placebo-controlled study. Intensive Care Med 11:288–294PubMedCrossRef
192.
Munster AM, Moran KT, Thupari J, Allo M, Winchurch RA (1987) Prophylactic intravenous immunoglobulin replacement in high-risk burn patients. J Burn Care Rehabil 8:376–380PubMedCrossRef
193.
Gooding AM, Bastian JF, Peterson BM, Wilson NW (1993) Safety and efficacy of intravenous immunoglobulin prophylaxis in pediatric head trauma patients: a double-blind controlled trial. J Crit Care 8:212–216PubMedCrossRef
194.
Douzinas EE, Pitaridis MT, Louris G, Andrianakis I, Katsouyanni K, Karmpaliotis D, Economidou J, Syfras D, Roussos C (2000) Prevention of infection in multiple trauma patients by high-dose intravenous immunoglobulins. Crit Care Med 28:8–15PubMedCrossRef
195.
Kress HG, Scheidewig C, Schmidt H, Silber R (1999) Reduced incidence of postoperative infection after intravenous administration of an immunoglobulin A- and immunoglobulin M-enriched preparation in anergic patients undergoing cardiac surgery. Crit Care Med 27:1281–1287PubMedCrossRef
196.
Chapel H, Dicato M, Gamm H, Brennan V, Ries F, Bunch C, Lee M (1994) Immunoglobulin replacement in patients with chronic lymphocytic leukaemia: a comparison of two dose regimes. Br J Haematol 88:209–212PubMedCrossRef
197.
Haywood CT, McGeer A, Low DE (1999) Clinical experience with 20 cases of group A streptococcus necrotizing fasciitis and myonecrosis: 1995 to 1997. Plast Reconstr Surg 103:1567–1573PubMedCrossRef
198.
Norrby-Teglund A, Muller MP, McGeer A, Gan BS, Guru V, Bohnen J, Thulin P, Low DE (2005) Successful management of severe group A streptococcal soft tissue infections using an aggressive medical regimen including intravenous polyspecific immunoglobulin together with a conservative surgical approach. Scand J Infect Dis 37:166–172PubMed
199.
Arnholm B, Lundqvist A, Stromberg A (2004) High-dose immunoglobulin—life-saving in invasive group A streptococcal infection. Report of eleven cases with only one fatality. Lakartidningen 101:2642–2644PubMed
200.
Korzets A, Ori Y, Zevin D, Weinberger M, Kesslin J, Seror D, Kuperman A, Gafter U (2002) Group A streptococcal bacteraemia and necrotizing fasciitis in a renal transplant patient: a case for intravenous immunoglobulin therapy. Nephrol Dial Transplant 17:150–152PubMedCrossRef
201.
Kalm O, Prellner K, Christensen P (1986) The effect of intravenous immunoglobulin treatment in recurrent acute otitis media. Int J Pediatr Otorhinolaryngol 11:237–246PubMedCrossRef
202.
Silk HJ, Ambrosino D, Geha RS (1990) Effect of intravenous gamma globulin therapy in IgG2 deficient and IgG2 sufficient children with recurrent infections and poor response to immunization with Haemophilus influenzae type b capsular polysaccharide antigen. Ann Allergy 64:21–25PubMed
203.
Huang YC, Lin TY, Lin YJ, Lien RI, Chou YH (2001) Prophylaxis of intravenous immunoglobulin and acyclovir in perinatal varicella. Eur J Pediatr 160:91–94PubMedCrossRef
204.
Lin SJ, Lin TY, Chiu CH, Huang YC (1995) Experience of intravenous immunoglobulin and acyclovir in neonates at risk for severe varicella infection—report of five cases. Zhonghua Min Guo Xiao Er Ke Yi Xue Hui Za Zhi 36:53–57PubMed
205.
Saitou M, Niitsuma K, Kasukawa R (1998) Two cases of severe adult varicella pneumonia. Nihon Kokyuki Gakkai Zasshi 36:251–255PubMed
206.
Shirai T, Sano K, Matsuyama S, Honjo Y, Takashima M, Sasada Y, Takayanagi S, Nagamatsu K, Nawano M, Fushimi M, Imokawa S, Sato A (1996) Varicella pneumonia in a healthy adult presenting with severe respiratory failure. Intern Med 35:315–318PubMedCrossRef
207.
Tokat O, Kelebek N, Turker G, Kahveci SF, Ozcan B (2001) Intravenous immunoglobulin in adult varicella pneumonia complicated by acute respiratory distress syndrome. J Int Med Res 29:252–255PubMed
208.
Chou DW, Lee CH, Chen CW, Chang HY, Hsiue TR (1999) Varicella pneumonia complicated by acute respiratory distress syndrome in an adult. J Formos Med Assoc 98:778–782PubMed
209.
Hara T, Mizuno Y, Igarashi H, Ueda K (1987) Intravenous gamma globulin therapy for thrombocytopenic purpura associated with active varicella infection. Eur J Pediatr 146:531–532PubMedCrossRef
210.
Kaneda K, Kojima K, Shinagawa K, Ishimaru F, Ikeda K, Niiya K, Harada M (2001) An adult patient with varicella preceded by acute thrombocytopenia. Rinsho Ketsueki 42:1142–1144PubMed
211.
Whitington PF, Hibbard JU (2004) High-dose immunoglobulin during pregnancy for recurrent neonatal haemochromatosis. Lancet 364:1690–1698PubMedCrossRef
212.
Hutton B, Sharma R, Fergusson D, Tinmouth A, Hebert P, Jamieson J, Walker M (2007) Use of intravenous immunoglobulin for treatment of recurrent miscarriage: a systematic review. BJOG 114:134–142PubMedCrossRef
213.
Porter TF, LaCoursiere Y, Scott JR (2006) Immunotherapy for recurrent miscarriage. Cochrane Database Syst Rev 4:CD000112
214.
The Practice Committee of the American Society for Reproductive Medicine (2006) Intravenous immunoglobulin (IVIG) and recurrent spontaneous pregnancy loss. Fertil Steril 86:S226–S227
215.
Christiansen OB, Pedersen B, Rosgaard A, Husth M (2002) A randomized, double-blind, placebo-controlled trial of intravenous immunoglobulin in the prevention of recurrent miscarriage: evidence for a therapeutic effect in women with secondary recurrent miscarriage. Hum Reprod 17:809–816PubMedCrossRef
216.
Daya S, Gunby J, Porter F, Scott J, Clark DA (1999) Critical analysis of intravenous immunoglobulin therapy for recurrent miscarriage. Hum Reprod Update 5:475–482PubMedCrossRef
217.
Perino A, Vassiliadis A, Vucetich A, Colacurci N, Menato G, Cignitti M, Semprini AE (1997) Short-term therapy for recurrent abortion using intravenous immunoglobulins: results of a double-blind placebo-controlled Italian study. Hum Reprod 12:2388–2392PubMedCrossRef
218.
Coulam CB, Krysa L, Stern JJ, Bustillo M (1995) Intravenous immunoglobulin for treatment of recurrent pregnancy loss. Am J Reprod Immunol 34:333–337PubMed
219.
Christiansen OB, Mathiesen O, Husth M, Rasmussen KL, Ingerslev HJ, Lauritsen JG, Grunnet N (1995) Placebo-controlled trial of treatment of unexplained secondary recurrent spontaneous abortions and recurrent late spontaneous abortions with i.v. immunoglobulin. Hum Reprod 10:2690–2695PubMed
220.
The German RSA/IVIG Group (1994) Intravenous immunoglobulin in the prevention of recurrent miscarriage. Br J Obstet Gynaecol 101:1072–1077
221.
Empson M, Lassere M, Craig J, Scott J (2005) Prevention of recurrent miscarriage for women with antiphospholipid antibody or lupus anticoagulant. Cochrane Database Syst Rev 2:CD002859PubMed
222.
Triolo G, Ferrante A, Ciccia F, Accardo-Palumbo A, Perino A, Castelli A, Giarratano A, Licata G (2003) Randomized study of subcutaneous low molecular weight heparin plus aspirin versus intravenous immunoglobulin in the treatment of recurrent fetal loss associated with antiphospholipid antibodies. Arthritis Rheum 48:728–731PubMedCrossRef
223.
Branch DW, Peaceman AM, Druzin M, Silver RK, El-Sayed Y, Silver RM, Esplin MS, Spinnato J, Harger J (2000) A multicenter, placebo-controlled pilot study of intravenous immune globulin treatment of antiphospholipid syndrome during pregnancy. The Pregnancy Loss Study Group. Am J Obstet Gynecol 182:122–127PubMedCrossRef
224.
Vaquero E, Lazzarin N, Valensise H, Menghini S, Di Pierro G, Cesa F, Romanini C (2001) Pregnancy outcome in recurrent spontaneous abortion associated with antiphospholipid antibodies: a comparative study of intravenous immunoglobulin versus prednisone plus low-dose aspirin. Am J Reprod Immunol 45:174–179PubMedCrossRef
225.
Clark AL, Branch DW, Silver RM, Harris EN, Pierangeli S, Spinnato JA (1999) Pregnancy complicated by the antiphospholipid syndrome: outcomes with intravenous immunoglobulin therapy. Obstet Gynecol 93:437–441PubMedCrossRef
226.
Sher G, Matzner W, Feinman M, Maassarani G, Zouves C, Chong P, Ching W (1998) The selective use of heparin/aspirin therapy, alone or in combination with intravenous immunoglobulin G, in the management of antiphospholipid antibody-positive women undergoing in vitro fertilization. Am J Reprod Immunol 40:74–82PubMed
227.
Marzusch K, Dietl J, Klein R, Hornung D, Neuer A, Berg PA (1996) Recurrent first trimester spontaneous abortion associated with antiphospholipid antibodies: a pilot study of treatment with intravenous immunoglobulin. Acta Obstet Gynecol Scand 75:922–926PubMedCrossRef
228.
Valensise H, Vaquero E, De Carolis C, Stipa E, Perricone R, Arduini D, Romanini C (1995) Normal fetal growth in women with antiphospholipid syndrome treated with high-dose intravenous immunoglobulin (IVIG). Prenat Diagn 15:509–517PubMedCrossRef
229.
Hockel M, Queisser-Luft A, Beck T, Zielberg R, Stopfkuchen H, Lissner R (1992) The effect of antenatal intravenous immunoglobulin on ascending intrauterine infection after preterm premature rupture of the membranes: a pilot study. J Perinat Med 20:101–110PubMedCrossRef
230.
Clark DA, Coulam CB, Stricker RB (2006) Is intravenous immunoglobulins (IVIG) efficacious in early pregnancy failure? A critical review and meta-analysis for patients who fail in vitro fertilization and embryo transfer (IVF). J Assist Reprod Genet 23:1–13PubMedCrossRef
231.
Stephenson MD, Fluker MR (2000) Treatment of repeated unexplained in vitro fertilization failure with intravenous immunoglobulin: a randomized, placebo-controlled Canadian trial. Fertil Steril 74:1108–1113PubMedCrossRef
232.
Bozkurt B, Villaneuva FS, Holubkov R, Tokarczyk T, Alvarez RJ Jr, MacGowan GA, Murali S, Rosenblum WD, Feldman AM, McNamara DM (1999) Intravenous immune globulin in the therapy of peripartum cardiomyopathy. J Am Coll Cardiol 34:177–180PubMedCrossRef
233.
Kishimoto C, Shioji K, Kinoshita M, Iwase T, Tamaki S, Fujii M, Murashige A, Maruhashi H, Takeda S, Nonogi H, Hashimoto T (2003) Treatment of acute inflammatory cardiomyopathy with intravenous immunoglobulin ameliorates left ventricular function associated with suppression of inflammatory cytokines and decreased oxidative stress. Int J Cardiol 91:173–178PubMedCrossRef
234.
Drucker NA, Colan SD, Lewis AB, Beiser AS, Wessel DL, Takahashi M, Baker AL, Perez-Atayde AR, Newburger JW (1994) Gamma-globulin treatment of acute myocarditis in the pediatric population. Circulation 89:252–257PubMed
235.
Durongpisitkul K, Gururaj VJ, Park JM, Martin CF (1995) The prevention of coronary artery aneurysm in Kawasaki disease: a meta-analysis on the efficacy of aspirin and immunoglobulin treatment. Pediatrics 96:1057–1061PubMed
236.
Oates-Whitehead RM, Baumer JH, Haines L, Love S, Maconochie IK, Gupta A, Roman K, Dua JS, Flynn I (2003) Intravenous immunoglobulin for the treatment of Kawasaki disease in children. Cochrane Database Syst Rev 4:CD004000PubMed
237.
Newburger JW, Takahashi M, Burns JC, Beiser AS, Chung KJ, Duffy CE, Glode MP, Mason WH, Reddy V, Sanders SP et al (1986) The treatment of Kawasaki syndrome with intravenous gamma globulin. N Engl J Med 315:341–347PubMed
238.
Khowsathit P, Hong-Hgam C, Khositseth A, Wanitkun S (2002) Treatment of Kawasaki disease with a moderate dose (1 g/kg) of intravenous immunoglobulin. J Med Assoc Thai 85(Suppl 4):S1121–S1126PubMed
239.
Tsai MH, Huang YC, Yen MH, Li CC, Chiu CH, Lin PY, Lin TY, Chang LY (2006) Clinical responses of patients with Kawasaki disease to different brands of intravenous immunoglobulin. J Pediatr 148:38–43PubMedCrossRef
240.
Qin LJ, Wang HW, Hu XF, Liu QJ, Shi H, Wei YX, Chen QJ, Cheng PX (2006) Therapeutic effectiveness of intravenous immunoglobulin at 1 g/kg and 2 g/kg on Kawasaki disease: a comparative and follow-up study. Zhonghua Er Ke Za Zhi 44:891–895PubMed
241.
Sakata K, Hamaoka K, Ozawa S, Niboshi A, Yoshihara T, Nishiki T, Nakagawa Y, Kazuta K, Morimoto Y, Kamiya Y, Yamamoto T, Horii Y, Kido S (2007) A randomized prospective study on the use of 2 g-IVIG or 1 g-IVIG as therapy for Kawasaki disease. Eur J Pediatr 166:565–571PubMedCrossRef
242.
Newburger JW, Takahashi M, Beiser AS, Burns JC, Bastian J, Chung KJ, Colan SD, Duffy CE, Fulton DR, Glode MP et al (1991) A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. N Engl J Med 324:1633–1639PubMed
243.
Voss LM, Wilson NJ, Neutze JM, Whitlock RM, Ameratunga RV, Cairns LM, Lennon DR (2001) Intravenous immunoglobulin in acute rheumatic fever: a randomized controlled trial. Circulation 103:401–406PubMed
244.
John R, Lietz K, Burke E, Ankersmit J, Mancini D, Suciu-Foca N, Edwards N, Rose E, Oz M, Itescu S (1999) Intravenous immunoglobulin reduces anti-HLA alloreactivity and shortens waiting time to cardiac transplantation in highly sensitized left ventricular assist device recipients. Circulation 100:II229–II235PubMed
245.
Drakos SG, Kfoury AG, Long JW, Stringham JC, Fuller TC, Nelson KE, Campbell BK, Gilbert EM, Renlund DG (2006) Low-dose prophylactic intravenous immunoglobulin does not prevent HLA sensitization in left ventricular assist device recipients. Ann Thorac Surg 82:889–893PubMedCrossRef
246.
Meyer SR, Ross DB, Forbes K, Hawkins LE, Halpin AM, Nahirniak SN, Rutledge JM, Rebeyka IM, Campbell PM (2007) Failure of prophylactic intravenous immunoglobulin to prevent sensitization to cryopreserved allograft tissue used in congenital cardiac surgery. J Thorac Cardiovasc Surg 133:1517–1523PubMedCrossRef
247.
Letko E, Bhol K, Foster CS, Ahmed AR (2000) Linear IgA bullous disease limited to the eye: a diagnostic dilemma: response to intravenous immunoglobulin therapy. Ophthalmology 107:1524–1528PubMedCrossRef
248.
Noseworthy JH, O'Brien PC, Petterson TM, Weis J, Stevens L, Peterson WK, Sneve D, Cross SA, Leavitt JA, Auger RG, Weinshenker BG, Dodick DW, Wingerchuk DM, Rodriguez M (2001) A randomized trial of intravenous immunoglobulin in inflammatory demyelinating optic neuritis. Neurology 56:1514–1522PubMed
249.
Roed HG, Langkilde A, Sellebjerg F, Lauritzen M, Bang P, Morup A, Frederiksen JL (2005) A double-blind, randomized trial of IV immunoglobulin treatment in acute optic neuritis. Neurology 64:804–810PubMed
250.
Symon Z, Schneebaum N, Eyal A, Tal S, Rozen N, Shoenfeld Y (2005) Successful intravenous immunoglobulin therapy for resistant inflammatory pseudotumor of the orbit. Thyroid 15:398–399PubMedCrossRef
251.
Cassoux N, Goichot-Bonnat L, Karmochkine M, Georges F, Kullmann N, Lehoang P, Kazatchkine M (2002) Efficacy of intravenous immunoglobulin in the treatment of Birdshot retinochoroiditis. J Fr Ophtalmol 25:23–30PubMed
252.
Shambal S, Lindner A, Zierz S (1998) Successful treatment of orbital myositis with intravenous immunoglobulins. Muscle Nerve 21:1359–1360PubMedCrossRef
253.
Rosenbaum JT, George RK, Gordon C (1999) The treatment of refractory uveitis with intravenous immunoglobulin. Am J Ophthalmol 127:545–549PubMedCrossRef
254.
Onal S, Foster CS, Ahmed AR (2006) Efficacy of intravenous immunoglobulin treatment in refractory uveitis. Ocul Immunol Inflamm 14:367–374PubMedCrossRef
255.
Baschieri L, Antonelli A, Nardi S, Alberti B, Lepri A, Canapicchi R, Fallahi P (1997) Intravenous immunoglobulin versus corticosteroid in treatment of Graves' ophthalmopathy. Thyroid 7:579–585PubMedCrossRef
256.
Kahaly G, Pitz S, Muller-Forell W, Hommel G (1996) Randomized trial of intravenous immunoglobulins versus prednisolone in Graves' ophthalmopathy. Clin Exp Immunol 106:197–202PubMedCrossRef
257.
Guy J, Aptsiauri N (1999) Treatment of paraneoplastic visual loss with intravenous immunoglobulin: report of 3 cases. Arch Ophthalmol 117:471–477PubMed
258.
Subhadra C, Dudek AZ, Rath PP, Lee MS (2008) Improvement in visual fields in a patient with melanoma-associated retinopathy treated with intravenous immunoglobulin. J Neuroophthalmol 28:23–26PubMed
259.
Floccari F, Cosentini V, Giacobbe M, Coppolino G, Campo S, Bolignano D, Tripodo D, Nostro L, Buemi M (2008) A case-by-case protocol of membranous nephropathy treatment with endovenous infusion of high doses of human immunoglobulins. Nephron Clin Pract 108:c113–c120PubMedCrossRef
260.
Palla R, Cirami C, Panichi V, Bianchi AM, Parrini M, Grazi G (1991) Intravenous immunoglobulin therapy of membranous nephropathy: efficacy and safety. Clin Nephrol 35:98–104PubMed
261.
Yokoyama H, Goshima S, Wada T, Takaeda M, Furuichi K, Kobayashi K, Kida H (1999) The short- and long-term outcomes of membranous nephropathy treated with intravenous immune globulin therapy. Kanazawa Study Group for Renal Diseases and Hypertension. Nephrol Dial Transplant 14:2379–2386PubMedCrossRef
262.
Rasche FM, Keller F, Lepper PM, Aymanns C, Karges W, Sailer LC, Muller L, Czock D (2006) High-dose intravenous immunoglobulin pulse therapy in patients with progressive immunoglobulin A nephropathy: a long-term follow-up. Clin Exp Immunol 146:47–53PubMedCrossRef
263.
Sener A, House AA, Jevnikar AM, Boudville N, McAlister VC, Muirhead N, Rehman F, Luke PP (2006) Intravenous immunoglobulin as a treatment for BK virus associated nephropathy: one-year follow-up of renal allograft recipients. Transplantation 81:117–120PubMedCrossRef
264.
Sharma AP, Moussa M, Casier S, Rehman F, Filler G, Grimmer J (2008) Intravenous immunoglobulin as rescue therapy for BK virus nephropathy. Pediatr Transplant 13:123–129PubMedCrossRef
265.
Ito-Ihara T, Ono T, Nogaki F, Suyama K, Tanaka M, Yonemoto S, Fukatsu A, Kita T, Suzuki K, Muso E (2006) Clinical efficacy of intravenous immunoglobulin for patients with MPO-ANCA-associated rapidly progressive glomerulonephritis. Nephron Clin Pract 102:c35–c42PubMedCrossRef
266.
Basok A, Shnaider A, Tovbin D, Rogachev B (2001) Successful use of high dose intravenous immunoglobulin in rapidly progressive crescentic glomerulonephritis with vasculitis. Isr Med Assoc J 3:453–454PubMed
267.
Tuso P, Moudgil A, Hay J, Goodman D, Kamil E, Koyyana R, Jordan SC (1992) Treatment of antineutrophil cytoplasmic autoantibody-positive systemic vasculitis and glomerulonephritis with pooled intravenous gamma globulin. Am J Kidney Dis 20:504–508PubMed
268.
Billing H, Rieger S, Ovens J, Susal C, Melk A, Waldherr R, Opelz G, Tonshoff B (2008) Successful treatment of chronic antibody-mediated rejection with IVIG and rituximab in pediatric renal transplant recipients. Transplantation 86:1214–1221PubMedCrossRef
269.
Yang YW, Lin WC, Wu MS, Lee PH, Tsai MK (2008) Early diagnosis and successful treatment of acute antibody-mediated rejection of a renal transplant. Exp Clin Transplant 6:211–214PubMed
270.
Furth S, Neu AM, Hart J, Zachary A, Colombani P, Fivush BA (1999) Plasmapheresis, intravenous cytomegalovirus-specific immunoglobulin and reversal of antibody-mediated rejection in a pediatric renal transplant recipient: a case report. Pediatr Transplant 3:146–149PubMedCrossRef
271.
Jordan SC, Quartel AW, Czer LS, Admon D, Chen G, Fishbein MC, Schwieger J, Steiner RW, Davis C, Tyan DB (1998) Posttransplant therapy using high-dose human immunoglobulin (intravenous gamma globulin) to control acute humoral rejection in renal and cardiac allograft recipients and potential mechanism of action. Transplantation 66:800–805PubMedCrossRef
272.
Boletis JN, Ioannidis JP, Boki KA, Moutsopoulos HM (1999) Intravenous immunoglobulin compared with cyclophosphamide for proliferative lupus nephritis. Lancet 354:569–570PubMedCrossRef
273.
Levy Y, Sherer Y, George J, Rovensky J, Lukac J, Rauova L, Poprac P, Langevitz P, Fabbrizzi F, Shoenfeld Y (2000) Intravenous immunoglobulin treatment of lupus nephritis. Semin Arthritis Rheum 29:321–327PubMedCrossRef
274.
Meissner M, Sherer Y, Levy Y, Chwalinska-Sadowska H, Langevitz P, Shoenfeld Y (2000) Intravenous immunoglobulin therapy in a patient with lupus serositis and nephritis. Rheumatol Int 19:199–201PubMedCrossRef
275.
Arahata H, Migita K, Izumoto H, Miyashita T, Munakata H, Nakamura H, Tominaga M, Origuchi T, Kawabe Y, Hida A, Taguchi T, Eguchi K (1999) Successful treatment of rapidly progressive lupus nephritis associated with anti-MPO antibodies by intravenous immunoglobulins. Clin Rheumatol 18:77–81PubMedCrossRef
276.
Razzaque Ahmed A (2001) Intravenous immunoglobulin therapy in the treatment of patients with pemphigus vulgaris unresponsive to conventional immunosuppressive treatment. J Am Acad Dermatol 45:679–690CrossRef
277.
Baum S, Scope A, Barzilai A et al (2006) The role of IVIG treatment in severe pemphigus vulgaris. J Eur Acad Dermatol Venereol 20:548–552PubMedCrossRef
278.
Bystryn JC, Jiao D, Natow S (2002) Treatment of pemphigus with intravenous immunoglobulin. J Am Acad Dermatol 47:358–363PubMedCrossRef
279.
Sami N, Qureshi A, Ruocco E et al (2002) Corticosteroid-sparing effect of intravenous immunoglobulin therapy in patients with pemphigus vulgaris. Arch Dermatol 138:1158–1162PubMedCrossRef
280.
Wetter DA, Davis MD, Yiannias J et al (2005) Effectiveness of intravenous immunoglobulin therapy for skin disease other than Toxic Epidermal Necrolysis: a retrospective review of Mayo Clinic experience. Mayo Clinic Proc 80:41–47CrossRef
281.
Razzaque Ahmed A, Sami N (2002) Intravenous immunoglobulin therapy for patients with pemphigus foliaceus unresponsive to conventional treatment. J Am Acad Dermatol 46:42–49PubMedCrossRef
282.
Sami N, Bhol KC, Razzaque Ahmed A (2002) Influence of IVIg therapy on autoantibody titers to desmoglein 1 in patients with pemphigus foliaceus. Clin Immunol 105:192–198PubMedCrossRef
283.
Sami N, Qureshi A, Razzaque Ahmed A (2002) Steroid sparing effect of intravenous immunoglobulin therapy in patients with pemphigus foliaceus. Eur J Dermatol 12:174–178PubMed
284.
Razzaque Ahmed A (2001) Intravenous immunoglobulin therapy for patients with bullous pemphigoid unresponsive to conventional immunosuppressive treatment. J Am Acad Dermatol 45:825–835CrossRef
285.
Engineer L, Razzaque Ahmed A (2001) Role of intravenous immunoglobulin in the treatment of bullous pemphigoid: analysis of current data. J Am Acad Dermatol 44:83–88PubMed
286.
Sami N, Bhol KC, Razzaque Ahmed A (2002) Treatment of oral pemphigoid with intravenous immunoglobulin as monotherapy. Long-term follow-up: influence of treatment on antibody titers to human alpha6 integrin. Clin Exp Immunol 129:533–540PubMedCrossRef
287.
Hern S, Harman K, Bhogal BS et al (1998) A severe persistent case of pemphigoid gestationis treated with intravenous immunoglobulin and cyclosporin. Clin Exp Dermatol 23:185–188PubMedCrossRef
288.
Prins C, Vittorio C, Padilla RS et al (2003) Effect of high-dose intravenous immunoglobulin therapy in Stevens–Johnson syndrome: a retrospective, multicenter study. Dermatology 207:96–99PubMedCrossRef
289.
Morici MV, Wesley G, Shetty AK et al (2000) Intravenous immunoglobulin therapy for children with Stevens–Johnson syndrome. J Rheumatol 27:2494–2497PubMed
290.
Al-Mutairi N, Arun J, Osama NE et al (2004) Prospective, noncomparative open study from Kuwait of the role of intravenous immunoglobulin in the treatment of toxic epidermal necrolysis. Int J Dermatol 43:847–851PubMedCrossRef
291.
Campione E, Marulli GC, Carrozzo AM et al (2003) High-dose intravenous immunoglobulin for severe drug reactions: efficacy in toxic epidermal necrolysis. Acta Derm Venereol 83:430–432PubMed
292.
Bachot N, Revuz J, Roujeau JC (2003) Intravenous immunoglobulin treatment for Stevens–Johnson syndrome and toxic epidermal necrolysis: a prospective noncomparative study showing no benefit on mortality or progression. Arch Dermatol 139:33–36PubMedCrossRef
293.
Spornraft-Ragaller P, Theilen H, Gottschlich GS, Ragaller M (2006) Treatment of toxic epidermal necrolysis. Experience with 9 patients with consideration of intravenous immunoglobulin. Hautarzt 57:185–194PubMedCrossRef
294.
Nasser M, Bitterman-Deutsch O, Nassar F (2005) Intravenous immunoglobulin for treatment of toxic epidermal necrolysis. Am J Med Sci 329:95–98PubMedCrossRef
295.
Metry D, Jung P, Levy ML (2003) Use of intravenous immunoglobulin in children with Stevens–Johnson syndrome and toxic epidermal necrolysis: seven cases and review of the literature. Pediatrics 112:1430–1436PubMedCrossRef
296.
Prins C, Kerdel FA, Padilla RS et al (2003) Treatment of toxic epidermal necrolysis with high dose intravenous immunoglobulins: multicenter retrospective analysis of 48 consecutive cases. Arch Dermatol 139:26–32PubMedCrossRef
297.
Trent JT, Kirsner RS, Romanelli P, Kerdel FA (2003) Analysis of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis using SCORTEN: the University of Miami Experience. Arch Dermatol 139:39–43PubMedCrossRef
298.
Tristani-Firouzi P, Petersen MJ, Saffle JR et al (2002) Treatment of toxic epidermal necrolysis with intravenous immunoglobulin in children. J Am Acad Dermatol 47:548–552PubMedCrossRef
299.
Shortt R, Gomez M, Mittman N, Cartotto R (2004) Intravenous immunoglobulin does not improve outcome in toxic epidermal necrolysis. J Burn Care Rehabil 25:246–255PubMedCrossRef
300.
Paul C, Lahfa M, Bachelez H et al (2002) A randomized controlled evaluator-blinded trial of intravenous immunoglobulin in adults with severe atopic dermatitis. Br J Dermatol 147:518–522PubMedCrossRef
301.
Jolles S, Sewell C, Webster D et al (2003) Adjunctive high-dose intravenous immunoglobulin treatment for resistant atopic dermatitis: efficacy and effects on intracellular cytokine levels and CD4 counts. Acta Derm Venereol 83:433–437PubMedCrossRef
302.
Jolles S, Hughes J, Rustin M (2000) The treatment of atopic dermatitis with adjunctive high dose intravenous immunoglobulin: a report of three patients and review of the literature. Br J Dermatol 142:551–554PubMedCrossRef
303.
Wakim M, Alazard M, Yajima A et al (1998) High dose immunoglobulin in atopic dermatitis and hyper-IgE syndrome. Ann Allergy Asthma Immunol 81:153–158PubMedCrossRef
304.
Jolles S (2002) A review of high-dose intravenous immunoglobulin treatment for atopic dermatitis. Clin Exp Dermatol 27:3–7PubMedCrossRef
305.
O'Donnell BF, Barr RM, Black AK et al (1998) Intravenous immunoglobulin un autoimmune chronic urticaria. Br J Dermatol 138:101–106PubMedCrossRef
306.
Kroiss M, Vogt T, Landthaler M et al (2000) The effectiveness of low dose intravenous immunoglobulin in chronic urticaria. Acta Derm Venereol 80:225PubMedCrossRef
307.
Dawn G, Urcelay M, Ah-Weng A et al (2003) Effect of high-dose intravenous immunoglobulin delayed pressure urticaria. Br J Dermatol 149:836–840PubMedCrossRef
308.
Puech-Plottova I, Michel JL, Rouchouse B et al (2000) Solar urticaria: one case treated by intravenous immunoglobulin. Ann Dermatol Venereol 127:831–835PubMed
309.
Darras S, Ségrad M, Mortier L et al (2004) Treatment of solar urticaria by intravenous immunoglobulins and PUVA therapy. Ann Dermatol Venereol 131:65–69PubMedCrossRef
310.
Orson FM (2003) Intravenous immunoglobulin therapy suppresses manifestations of the angioedema with hypereosinophilia syndrome. Am J Med Sci 326:94–97PubMedCrossRef
311.
Gurmin V, Mediwake R, Fernando M et al (2002) Psoriasis: response to high-dose intravenous immunoglobulin in three patients. Br J Dermatol 147:554–557PubMedCrossRef
312.
Cummins DL, Anhalt GJ, Monahan T, Meyerle JH (2007) Treatment of pyoderma gangrenosum with intravenous immunoglobulin. Br J Dermatol 157:1235–1239PubMedCrossRef
313.
Meyer N, Ferraro V, Mignard MH et al (2006) Pyoderma gangrenosum treated with high-dose intravenous immunoglobulins: two cases and review of literature. Clin Drug Investig 26:541–546PubMedCrossRef
314.
Chung HJ, Chung KY (2004) Nephrogenic fibrosing dermopathy: response to high-dose intravenous immunoglobulin. Br J Dermatol 150:596–597PubMedCrossRef
315.
Antonelli A, Navarranne A, Palla R et al (1994) Pretibial myxedema and high-dose intravenous immunoglobulin treatment. Thyroid 4:399–408PubMedCrossRef
316.
Blum M, Wigley FM, Hummers LK (2008) Scleromyxedema. A case series highlighting long-term outcomes of treatment with intravenous immunoglobulin (IVIG). Medicine 87:10–20PubMedCrossRef
317.
Kulczycki A, Nelson M, Eisen A, Heffernan M (2003) Scleromyxoedema: treatment of cutaneous and systemic manifestations with high-dose intravenous immunoglobulin. Br J Dermatol 149:1276–1281PubMedCrossRef
318.
Lister RK, Jolles S, Whittaker S, Black C, Forgacs I, Cramp M, Potter M, Rustin MH (2000) Scleromyxedema: response to high-dose intravenous immunoglobulin (hdIVIg). J Am Acad Dermatol 43:403–408PubMedCrossRef
319.
Gholam P, Hartmann M, Enk A (2007) Arndt–Gottron scleromyxedema: successful therapy with intravenous immunoglobulins. Br J Dermatol 157:1058–1060PubMedCrossRef
320.
Majeski C, Taher M, Grewal P et al (2005) Combination oral prednisone and intravenous immunoglobulin in the treatment of scleromyxedema. J Cutan Med Surg 9:99–104PubMedCrossRef
321.
Körber A, Franckson T, Grabbe S, Dissemond J (2007) Successful therapy of scleromyxedema Arndt–Gottron with low-dose intravenous immunoglobulin. Eur Acad Dermatol Venereol 21:553–554
322.
Topf S, Simon M, Schell H, Lüftl M (2007) Marked improvement in scleromyxedema with high-dose immunoglobulin. Hautarzt 58:525–528PubMedCrossRef
323.
Wojas-Pelc A, Błaszczyk M, Glinska M, Jabłonska S (2005) Tumorous variant of scleromyxedema. Successful therapy with intravenous immunoglobulins. Eur Acad Dermatol Venereol 19:462–465CrossRef
324.
Jolles S, Hughes J (2006) Use of IGIV in the treatment of atopic dermatitis, urticaria, scleromyxedema, pyoderma gangrenosum, psoriasis, and pretibial myxedema. Int Immunopharmacol 6:579–591PubMedCrossRef
325.
Boonyaleepun S, Boonyaleepun C, Schlactus JL (1999) Effect of IVIG on the hair regrowth in a common variable immune deficiency patient with alopecia universalis. Asian Pac J Allergy Immunol 17:59–62PubMed
326.
Carmeli Y, Mevorach D, Kaminski N, Raz E (1994) Regression of Kaposi's sarcoma after intravenous immunoglobulin treatment for polymyositis. Cancer 73:2859–2891PubMedCrossRef
327.
Schachter J, Katz U, Mahrer A et al (2007) Efficacy and safety of intravenous immunoglobulin in patients with metastatic melanoma. Ann N Y Acad Sci 1110:305–314PubMedCrossRef
328.
Plevova P, Blazek B (1997) Intravenous immunoglobulin as prophylaxis of chemotherapy-induced oral mucositis. J Natl Cancer Inst 89:326–327PubMedCrossRef
329.
Murie-Fernandez M, Gurpide A, de la Cruz S, de Castro P (2006) Total remission of thymus carcinoma after treatment with intravenous immunoglobulin. Clin Transl Oncol 8:697–699PubMedCrossRef
330.
Agarwal S, Cunningham-Rundles C (2007) Thymoma and immunodeficiency (Good syndrome): a report of 2 unusual cases and review of the literature. Ann Allergy Asthma Immunol 98:185–190PubMedCrossRef
331.
Sharma KR, Cross J, Ayyar DR et al (2002) Diabetic demyelinating polyneuropathy responsive to intravenous immunoglobulin therapy. Arch Neurol 59:751–757PubMedCrossRef
332.
Kawagashira Y, Watanabe H, Oki Y et al (2007) Intravenous immunoglobulin therapy markedly ameliorates muscle weakness and severe pain in proximal diabetic neuropathy. J Neurol Neurosurg Psychiatry 78:899–901PubMedCrossRef
333.
Uluduz D, Bozluolcay M, Ince B, Kiziltan M (2005) Simultaneous multiple cranial nerve neuropathies and intravenous immunoglobulin treatment in diabetes mellitus. Neurol India 54:308–309CrossRef
334.
Wada Y, Yanagihara C, Nishimura Y, Oka N (2007) A case of diabetic amyotrophy with severe atrophy and weakness of shoulder girdle muscles showing good response to intravenous immune globulin. Diabetes Res Clin Pract 75:107–110PubMedCrossRef
335.
Melcher M, Olson JL, Baxter-Lowe LA et al (2006) Antibody-mediated rejection of a pancreas allograft. Am J Transplant 6:423–428PubMedCrossRef
336.
Reisin R, Zurrú C, Buso C et al (2005) Multifocal motor neuropath, type 1 diabetes and asymptomatic Hashimoto's thyroiditis: an unusual association. Neuromuscul Disord 15:358–360PubMedCrossRef
337.
Toscano A, Rodolico C, Benvenga S et al (2002) Multifocal motor neuropathy and asymptomatic Hashimoto's thyroiditis: first report of association. Neuromuscul Disord 12:566–568PubMedCrossRef
338.
Yuceyar N, Karadeniz M, Erdogan M et al (2007) Thyrotoxic autoimmune encephalopathy in a female patient: only partial response to typical immunosuppressant treatment and remission after thyroidectomy. Clin Neurol Neurosurg 109:458–462PubMedCrossRef
339.
Cappa M, Bertini E, Del Balzo P et al (1994) High dose immunoglobulin IV treatment in adrenoleukodystrophy. J Neurol Neurosurg Psychiatry 57(Supplement):69–70PubMedCrossRef
340.
Kohler W (1994) Discussion on: high dose immunoglobulin IV treatment in adrenoleukodystrophy. J Neurol Neurosurg Psychiatry 57(Suppl):71CrossRef
341.
Agraharkar M, Fahlen M, Siddiqui M et al (2000) Waterhouse–Friderichsen syndrome and bilateral renal cortical necrosis in meningococcal sepsis. Am J Kidney Disease 36:396–400CrossRef
342.
Antonelli A, Gambuzza C, Alberti B et al (1992) Autoimmune polyendocrine syndrome. Treatment with intravenous immunoglobulins. Clin Ther 141:43–48
343.
Leen WG, Weemaes CM, Verbeek MM, Willemsen MA, Rotteveel JJ (2008) Rituximab and intravenous immunoglobulins for relapsing postinfectious opsoclonus-myoclonus syndrome. Pediatr Neurol 39:213–217PubMedCrossRef
344.
Unal A, Sumer MM, Atasoy HT, Atasoy N (2004) Treatment of idiopathic opsoclonus-myoclonus syndrome with intravenous immunoglobulin. Neurol India 52:520–521PubMed
345.
Glatz K, Meinck HM, Wildemann B (2003) Parainfectious opsoclonus-myoclonus syndrome: high dose intravenous immunoglobulins are effective. J Neurol Neurosurg Psychiatry 74:279–280PubMedCrossRef
346.
Pranzatelli MR, Tate ED, Kinsbourne M, Caviness VS Jr, Mishra B (2002) Forty-one year follow-up of childhood-onset opsoclonus-myoclonus-ataxia: cerebellar atrophy, multiphasic relapses, and response to IVIG. Mov Disord 17:1387–1390PubMedCrossRef
347.
Borgna-Pignatti C, Balter R, Marradi P, Colamaria V (1996) Treatment with intravenously administered immunoglobulins of the neuroblastoma-associated opsoclonus-myoclonus. J Pediatr 129:179–180PubMed
348.
Pless M, Ronthal M (1996) Treatment of opsoclonus-myoclonus with high-dose intravenous immunoglobulin. Neurology 46:583–584PubMed
349.
Petruzzi MJ, de Alarcon PA (1995) Neuroblastoma-associated opsoclonus-myoclonus treated with intravenously administered immune globulin G. J Pediatr 127:328–329PubMedCrossRef
350.
Sugie H, Sugie Y, Akimoto H, Endo K, Shirai M, Ito M (1992) High-dose i.v. human immunoglobulin in a case with infantile opsoclonus polymyoclonia syndrome. Acta Paediatr 81:371–372PubMedCrossRef
351.
Bataller L, Graus F, Saiz A, Vilchez JJ (2001) Clinical outcome in adult onset idiopathic or paraneoplastic opsoclonus-myoclonus. Brain 124:437–443PubMedCrossRef
352.
Perlmutter SJ, Leitman SF, Garvey MA, Hamburger S, Feldman E, Leonard HL, Swedo SE (1999) Therapeutic plasma exchange and intravenous immunoglobulin for obsessive-compulsive disorder and tic disorders in childhood. Lancet 354:1153–1158PubMedCrossRef
353.
Fazekas F, Lublin FD, Li D, Freedman MS, Hartung HP, Rieckmann P, Sorensen PS, Maas-Enriquez M, Sommerauer B, Hanna K (2008) Intravenous immunoglobulin in relapsing-remitting multiple sclerosis: a dose-finding trial. Neurology 71:265–271PubMedCrossRef
354.
Pohlau D, Przuntek H, Sailer M, Bethke F, Koehler J, Konig N, Heesen C, Spath P, Andresen I (2007) Intravenous immunoglobulin in primary and secondary chronic progressive multiple sclerosis: a randomized placebo controlled multicentre study. Mult Scler 13:1107–1117PubMedCrossRef
355.
Petereit HF, Reske D, Pukrop R, Maas-Enriquez M, Japp G, Jongen PJ, Kolmel HW, Merkelbach S, Hartung HP, Heiss WD, Hommes OR (2006) No effect of intravenous immunoglobulins on cytokine-producing lymphocytes in secondary progressive multiple sclerosis. Mult Scler 12:66–71PubMedCrossRef
356.
Haas J, Maas-Enriquez M, Hartung HP (2005) Intravenous immunoglobulins in the treatment of relapsing remitting multiple sclerosis—results of a retrospective multicenter observational study over five years. Mult Scler 11:562–567PubMedCrossRef
357.
Hommes OR, Sorensen PS, Fazekas F, Enriquez MM, Koelmel HW, Fernandez O, Pozzilli C, O'Connor P (2004) Intravenous immunoglobulin in secondary progressive multiple sclerosis: randomised placebo-controlled trial. Lancet 364:1149–1156PubMedCrossRef
358.
Sorensen PS, Fazekas F, Lee M (2002) Intravenous immunoglobulin G for the treatment of relapsing–remitting multiple sclerosis: a meta-analysis. Eur J Neurol 9:557–563PubMedCrossRef
359.
Fazekas F, Strasser-Fuchs S, Hartung HP (1998) Intravenous immunoglobulins in therapy of intermittent multiple sclerosis. An update. Nervenarzt 69:361–365PubMedCrossRef
360.
Achiron A, Gabbay U, Gilad R, Hassin-Baer S, Barak Y, Gornish M, Elizur A, Goldhammer Y, Sarova-Pinhas I (1998) Intravenous immunoglobulin treatment in multiple sclerosis. Effect on relapses. Neurology 50:398–402PubMed
361.
Sorensen PS, Wanscher B, Schreiber K, Blinkenberg M, Jensen CV, Ravnborg M (1997) A double-blind, cross-over trial of intravenous immunoglobulin G in multiple sclerosis: preliminary results. Mult Scler 3:145–148PubMedCrossRef
362.
Hughes RA, Swan AV, Raphael JC, Annane D, van Koningsveld R, van Doorn PA (2007) Immunotherapy for Guillain–Barré syndrome: a systematic review. Brain 130:2245–2257PubMedCrossRef
363.
Yata J, Nihei K, Ohya T, Hirano Y, Momoi M, Maekawa K, Sakakihara Y (2003) High-dose immunoglobulin therapy for Guillain–Barré syndrome in Japanese children. Pediatr Int 45:543–549PubMedCrossRef
364.
Raphael JC, Chevret S, Harboun M, Jars-Guincestre MC (2001) Intravenous immune globulins in patients with Guillain–Barré syndrome and contraindications to plasma exchange: 3 days versus 6 days. J Neurol Neurosurg Psychiatry 71:235–238PubMedCrossRef
365.
Kuwabara S, Mori M, Ogawara K, Hattori T, Oda S, Koga M, Yuki N (2001) Intravenous immunoglobulin therapy for Guillain–Barré syndrome with IgG anti-GM1 antibody. Muscle Nerve 24:54–58PubMedCrossRef
366.
Plasma Exchange/Sandoglobulin Guillain–Barré Syndrome Trial Group (1997) Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain–Barré syndrome. Lancet 349:225–230CrossRef
367.
van der Meche FG (1994) Intravenous immune globulin in the Guillain–Barré syndrome. Clin Exp Immunol 97(Suppl 1):43–47PubMed
368.
Lunn MP, Nobile-Orazio E (2006) Immunotherapy for IgM anti-myelin-associated glycoprotein paraprotein-associated peripheral neuropathies. Cochrane Database Syst Rev 2:CD002827PubMed
369.
Comi G, Roveri L, Swan A, Willison H, Bojar M, Illa I, Karageorgiou C, Nobile-Orazio E, van den Bergh P, Swan T, Hughes R, Aubry J, Baumann N, Hadden R, Lunn M, Knapp M, Leger JM, Bouche P, Mazanec R, Meucci N, van der Meche F, Toyka K (2002) A randomised controlled trial of intravenous immunoglobulin in IgM paraprotein associated demyelinating neuropathy. J Neurol 249:1370–1377PubMedCrossRef
370.
Dalakas MC, Quarles RH, Farrer RG, Dambrosia J, Soueidan S, Stein DP, Cupler E, Sekul EA, Otero C (1996) A controlled study of intravenous immunoglobulin in demyelinating neuropathy with IgM gammopathy. Ann Neurol 40:792–795PubMedCrossRef
371.
Meucci N, Nobile-Orazio E, Scarlato G (1996) Intravenous immunoglobulin therapy in amyotrophic lateral sclerosis. J Neurol 243:117–120PubMedCrossRef
372.
Dalakas MC, Stein DP, Otero C, Sekul E, Cupler EJ, McCrosky S (1994) Effect of high-dose intravenous immunoglobulin on amyotrophic lateral sclerosis and multifocal motor neuropathy. Arch Neurol 51:861–864PubMed
373.
Bain PG, Motomura M, Newsom-Davis J, Misbah SA, Chapel HM, Lee ML, Vincent A, Lang B (1996) Effects of intravenous immunoglobulin on muscle weakness and calcium-channel autoantibodies in the Lambert–Eaton myasthenic syndrome. Neurology 47:678–683PubMed
374.
Karlson EW, Sudarsky L, Ruderman E, Pierson S, Scott M, Helfgott SM (1994) Treatment of stiff-man syndrome with intravenous immune globulin. Arthritis Rheum 37:915–918PubMedCrossRef
375.
Amato AA, Cornman EW, Kissel JT (1994) Treatment of stiff-man syndrome with intravenous immunoglobulin. Neurology 44:1652–1654PubMed
376.
Khanlou H, Eiger G (1999) Long-term remission of refractory stiff-man syndrome after treatment with intravenous immunoglobulin. Mayo Clin Proc 74:1231–1232PubMedCrossRef
377.
Dalakas MC, Fujii M, Li M, Lutfi B, Kyhos J, McElroy B (2001) High-dose intravenous immune globulin for stiff-person syndrome. N Engl J Med 345:1870–1876PubMedCrossRef
378.
Cappa M, Bertini E, del Balzo P, Cambiaso P, Di Biase A, Salvati S (1994) High dose immunoglobulin IV treatment in adrenoleukodystrophy. J Neurol Neurosurg Psychiatry 57(Suppl):69–70 discussion 71PubMedCrossRef
379.
van Rijckevorsel-Harmant K, Delire M, Schmitz-Moorman W, Wieser HG (1994) Treatment of refractory epilepsy with intravenous immunoglobulins. Results of the first double-blind/dose finding clinical study. Int J Clin Lab Res 24:162–166PubMedCrossRef
380.
Illum N, Taudorf K, Heilmann C, Smith T, Wulff K, Mansa B, Platz P (1990) Intravenous immunoglobulin: a single-blind trial in children with Lennox–Gastaut syndrome. Neuropediatrics 21:87–90PubMedCrossRef
381.
Mohr M, Englisch L, Roth A, Burchardi H, Zielmann S (1997) Effects of early treatment with immunoglobulin on critical illness polyneuropathy following multiple organ failure and gram-negative sepsis. Intensive Care Med 23:1144–1149PubMedCrossRef
382.
Wijdicks EF, Fulgham JR (1994) Failure of high dose intravenous immunoglobulins to alter the clinical course of critical illness polyneuropathy. Muscle Nerve 17:1494–1495PubMed
383.
Granata T, Fusco L, Gobbi G, Freri E, Ragona F, Broggi G, Mantegazza R, Giordano L, Villani F, Capovilla G, Vigevano F, Bernardina BD, Spreafico R, Antozzi C (2003) Experience with immunomodulatory treatments in Rasmussen's encephalitis. Neurology 61:1807–1810PubMed
384.
Villani F, Spreafico R, Farina L, Giovagnoli AR, Bernasconi P, Granata T, Avanzini G (2001) Positive response to immunomodulatory therapy in an adult patient with Rasmussen's encephalitis. Neurology 56:248–250PubMed
385.
Leach JP, Chadwick DW, Miles JB, Hart IK (1999) Improvement in adult-onset Rasmussen's encephalitis with long-term immunomodulatory therapy. Neurology 52:738–742PubMed
386.
Hart YM, Cortez M, Andermann F, Hwang P, Fish DR, Dulac O, Silver K, Fejerman N, Cross H, Sherwin A et al (1994) Medical treatment of Rasmussen's syndrome (chronic encephalitis and epilepsy): effect of high-dose steroids or immunoglobulins in 19 patients. Neurology 44:1030–1036PubMed
387.
Hughes RA, Donofrio P, Bril V, Dalakas MC, Deng C, Hanna K, Hartung HP, Latov N, Merkies IS, van Doorn PA (2008) Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial. Lancet Neurol 7:136–144PubMedCrossRef
388.
Hughes R, Bensa S, Willison H, Van den Bergh P, Comi G, Illa I, Nobile-Orazio E, van Doorn P, Dalakas M, Bojar M, Swan A (2001) Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 50:195–201PubMedCrossRef
389.
Mendell JR, Barohn RJ, Freimer ML, Kissel JT, King W, Nagaraja HN, Rice R, Campbell WW, Donofrio PD, Jackson CE, Lewis RA, Shy M, Simpson DM, Parry GJ, Rivner MH, Thornton CA, Bromberg MB, Tandan R, Harati Y, Giuliani MJ (2001) Randomized controlled trial of IVIg in untreated chronic inflammatory demyelinating polyradiculoneuropathy. Neurology 56:445–449PubMed
390.
Hahn AF, Bolton CF, Zochodne D, Feasby TE (1996) Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy. A double-blind, placebo-controlled, cross-over study. Brain 119(Pt 4):1067–1077PubMedCrossRef
391.
Gajdos P, Chevret S, Toyka K (2008) Intravenous immunoglobulin for myasthenia gravis. Cochrane Database Syst Rev 2:CD002277
392.
Zinman L, Ng E, Bril V (2007) IV immunoglobulin in patients with myasthenia gravis: a randomized controlled trial. Neurology 68:837–841PubMedCrossRef
393.
Wolfe GI, Barohn RJ, Foster BM, Jackson CE, Kissel JT, Day JW, Thornton CA, Nations SP, Bryan WW, Amato AA, Freimer ML, Parry GJ (2002) Randomized, controlled trial of intravenous immunoglobulin in myasthenia gravis. Muscle Nerve 26:549–552PubMedCrossRef
394.
Ronager J, Ravnborg M, Hermansen I, Vorstrup S (2001) Immunoglobulin treatment versus plasma exchange in patients with chronic moderate to severe myasthenia gravis. Artif Organs 25:967–973PubMedCrossRef
395.
Achiron A, Barak Y, Miron S, Sarova-Pinhas I (2000) Immunoglobulin treatment in refractory myasthenia gravis. Muscle Nerve 23:551–555PubMedCrossRef
396.
Fu DC, Montgomery JR (2008) High-dose, rapid-infusion IVIG in postvaccination acute disseminated encephalomyelitis. Neurology 71:294–295PubMedCrossRef
397.
Shahar E, Andraus J, Savitzki D, Pilar G, Zelnik N (2002) Outcome of severe encephalomyelitis in children: effect of high-dose methylprednisolone and immunoglobulins. J Child Neurol 17:810–814PubMedCrossRef
398.
Marchioni E, Marinou-Aktipi K, Uggetti C, Bottanelli M, Pichiecchio A, Soragna D, PiccoloG IF, Romani A, Ceroni M (2002) Effectiveness of intravenous immunoglobulin treatment in adult patients with steroid-resistant monophasic or recurrent acute disseminated encephalomyelitis. J Neurol 249:100–104PubMedCrossRef
399.
Straussberg R, Schonfeld T, Weitz R, Karmazyn B, Harel L (2001) Improvement of atypical acute disseminated encephalomyelitis with steroids and intravenous immunoglobulins. Pediatr Neurol 24:139–143PubMedCrossRef
400.
Andersen JB, Rasmussen LH, Herning M, Paerregaard A (2001) Dramatic improvement of severe acute disseminated encephalomyelitis after treatment with intravenous immunoglobulin in a three-year-old boy. Dev Med Child Neurol 43:136–138PubMedCrossRef
401.
Sahlas DJ, Miller SP, Guerin M, Veilleux M, Francis G (2000) Treatment of acute disseminated encephalomyelitis with intravenous immunoglobulin. Neurology 54:1370–1372PubMed
402.
DelGiudice-Asch G, Simon L, Schmeidler J, Cunningham-Rundles C, Hollander E (1999) Brief report: a pilot open clinical trial of intravenous immunoglobulin in childhood autism. J Autism Dev Disord 29:157–160PubMedCrossRef
403.
Quartier P, Debre M, de Blic J et al (1999) Early and prolonged intravenous immunoglobulin replacement therapy in childhood agammaglobulinemia: a retrospective survey of 31 patients. J Pediatr 134:589–596PubMedCrossRef
404.
Liese JG, Wintergerst U, Tympner KD, Belohradsky BH (1992) High- vs. low-dose immunoglobulin therapy in the long-term treatment of X-linked agammaglobulinemia. Am J Dis Child 146:335–339PubMed
405.
Aghamohammadi A, Moin M, Farhoudi A et al (2004) Efficacy of intravenous immunoglobulin on the prevention of pneumonia in patients with agammaglobulinemia. FEMS Immunol Med Microbiol 40:113–118PubMedCrossRef
406.
Nolte MT, Pirofsky B, Gerritz GA, Golding B (1979) Intravenous immunoglobulin therapy for antibody deficiency. Clin Exp Immunol 36:237–243PubMed
407.
Eijkhout HW, van der Meer JWM, Kallenberg CGM et al (2001) The effect of two different dosages of intravenous immunoglobulin on the incidence of recurrent infections in patients with primary hypogammaglobulinemia. Ann Int Med 135:165–174PubMed
408.
Litzman J, Jones A, Hann I et al (1996) Intravenous immunoglobulin, splenectomy and antibiotic prophylaxis in Wiscott–Aldrich syndrome. Arch Dis Child 75:436–439PubMedCrossRef
409.
Matamoros Flori N, Mila Llambi J, Hernandez Gonzalez M, Julia Benique MR (1993) New diagnostic and therapeutic aspects of hyper-IgE syndrome. Report of 3 cases. Med Clin (Barc) 101:138–140
410.
DeWitt CA, Bishop AB, Buescher LS, Stone SP (2006) Hyperimmunoglobulin E syndrome: two cases and a review of the literature. J Am Acad Dermatol 54:855–865PubMedCrossRef
411.
Wakim M, Alazard M, Yajima A, Speights D, Saxon A, Stiehm ER (1998) High dose intravenous immunoglobulin in atopic dermatitis and hyper-IgE syndrome. Ann Allergy Asthma Immunol 81:153–158PubMedCrossRef
412.
Shield JP, Strobel S, Levinsky RJ, Morgan G (1992) Immunodeficiency presenting as hypergammaglobulinaemia with IgG2 subclass deficiency. Lancet 340:448–450PubMedCrossRef
413.
Grob M, Joller-Jemelka HI, Grob PJ (1991) Deficiency in immunoglobulin subclasses as cause of increased infection susceptibility—a family study. Schweiz Med Wochenschr 121:133–144PubMed
414.
Chinratanapisit S, Tunsuriyawong P, Vichyanond P, Visitsunthorn N, Luangwedchakarn V, Jirapongsananuruk O (2005) Chronic rhinosinusitis and recurrent nasal polyps in two children with IgG subclass deficiency and review of the literature. J Med Assoc Thai 88(Suppl 8):S251–S258PubMed
415.
Nettagul R, Visitsunthorn N, Vichyanond P (2003) A case of IgG subclass deficiency with the initial presentation of transient hypogamma immunoglobulinemia of infancy and a review of IgG subclass deficiencies. J Med Assoc Thai 86:686–692PubMed
416.
Nordin U, Wannfors K, Colque-Navarro P, Mollby R, Heimdahl A (1995) Antibody response in patients with osteomyelitis of the mandible. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 79:429–435PubMedCrossRef
417.
Cheng YK, Decker PA, O'Byrne MM, Weiler CR (2006) Clinical and laboratory characteristics of 75 patients with specific polysaccharide antibody deficiency syndrome. Ann Allergy Asthma Immunol 97:306–311PubMedCrossRef
418.
Babovic-Vuksanovic D, Jacobson RM, Lindor NM, Weiler CR (2005) Selective antibody immune deficiency in a patient with Smith–Lemli–Opitz syndrome. J Inherit Metab Dis 28:181–186PubMedCrossRef
419.
Quartier P, Bustamante J, Sanal O, Plebani A, Debre M, Deville A, Litzman J, Levy J, Fermand JP, Lane P, Horneff G, Aksu G, Yalcin I, Davies G, Tezcan I, Ersoy F, Catalan N, Imai K, Fischer A, Durandy A (2004) Clinical, immunologic and genetic analysis of 29 patients with autosomal recessive hyper-IgM syndrome due to activation-induced cytidine deaminase deficiency. Clin Immunol 110:22–29PubMedCrossRef
420.
Bejaoui M, Mellouli F, Chouanine R, Dellagi K, Barbouche MR (2003) The hyper-IgM syndrome: 13 observations. Presse Med 32:544–549PubMed
421.
Ersoy F, Tezcan I, Sanal O (1992) Effects of intravenous immunoglobulin on clinical and immunological findings of patients with humoral immunodeficiency diseases. Turk J Pediatr 34:203–209PubMed
422.
Quezada A, Norambuena X, Gonzalez R, Ramos SM, Chavez A, Gonzalez S (2000) Non-X-linked hyperimmunoglobulin M syndrome with chronic interstitial pneumonitis. J Investig Allergol Clin Immunol 10:375–379PubMed
423.
Atarod L, Aghamohammadi A, Moin M, Kanegane H, Rezaei N, Rezaei Kalantari K, Amirzagar AA, Futatani T, Miyawaki M (2007) Successful management of neutropenia in a patient with CD40 ligand deficiency by immunoglobulin replacement therapy. Iran J Allergy Asthma Immunol 6:37–40PubMed
424.
Ma YC, Shyur SD, Huang LH, Wu JY, Lin SC (2004) Hyper-IgM syndrome: report of one case. Acta Paediatr Taiwan 45:334–339PubMed
425.
Hsueh KC, Chiu HH, Lin HC, Hsu CH, Tsai FJ (2005) Transient hypogammaglobulinemia of infancy presenting as Staphylococcus aureus sepsis with deep neck infection. J Microbiol Immunol Infect 38:141–144PubMed
426.
Benderly A, Pollack S, Etzioni A (1986) Transient hypogammaglobulinemia of infancy with severe bacterial infections and persistent IgA deficiency. Isr J Med Sci 22:393–396PubMed
427.
Buckley RH, Schiff SE, Schiff RI, Markert L, Williams LW, Roberts JL, Myers LA, Ward FE (1999) Hematopoietic stem-cell transplantation for the treatment of severe combined immunodeficiency. N Engl J Med 340:508–516PubMedCrossRef
428.
Busse PJ, Razvi S, Cunningham-Rundles C (2002) Efficacy of intravenous immunoglobulin in the prevention of pneumonia in patients with common variable immunodeficiency. J Allergy Clin Immunol 109:1001–1004PubMedCrossRef
Metadata
Title
Evidence for the Use of Intravenous Immunoglobulins—A Review of the Literature
Authors
Shaye Kivity
Uriel Katz
Natalie Daniel
Udi Nussinovitch
Neophytos Papageorgiou
Yehuda Shoenfeld
Publication date
01-04-2010
Publisher
Humana Press Inc
Published in
Clinical Reviews in Allergy & Immunology / Issue 2-3/2010
Print ISSN: 1080-0549
Electronic ISSN: 1559-0267
DOI
https://doi.org/10.1007/s12016-009-8155-9

Other articles of this Issue 2-3/2010

Clinical Reviews in Allergy & Immunology 2-3/2010 Go to the issue

OriginalPaper

The Premenstrual Syndrome and Fibromyalgia—Similarities and Common Features

OriginalPaper

Antiphospholipid Antibody-Mediated Reproductive Failure in Antiphospholipid Syndrome

OriginalPaper

Antifibrosis: To Reverse the Irreversible

OriginalPaper

Intravenous Immunoglobulin in Lupus Panniculitis

OriginalPaper

Diagnostic Challenges in Celiac Disease and the Role of the Tissue Transglutaminase–Neo-Epitope

OriginalPaper

High-Dose Intravenous Immunoglobulin (IVIG) Therapy in Autoimmune Skin Blistering Diseases
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits